Interleukin-12 in Combination with CTLA-4 Blockade Leads to T-cell Dependent Rejection of Advanced Stage Glioma by Vom Berg, Johannes
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Interleukin-12 in Combination with CTLA-4 Blockade Leads to T-cell
Dependent Rejection of Advanced Stage Glioma
Vom Berg, Johannes
Abstract: Unspecified
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-74786
Originally published at:
Vom Berg, Johannes. Interleukin-12 in Combination with CTLA-4 Blockade Leads to T-cell Dependent
Rejection of Advanced Stage Glioma. 2012, University of Zurich, Faculty of Medicine.
   
Interleukin-12 in Combination with CTLA-4 Blockade 
Leads to T-cell Dependent Rejection of Advanced Stage 
Glioma 
 
 
Dissertation 
zur 
Erlangung der Naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der 
Universität Zürich 
von 
 
 
Johannes Zacharias vom Berg 
aus 
Deutschland 
 
 
 
Promotionskomitee 
 
Prof. Dr. Burkhard Becher  
(Vorsitz und Leitung der Dissertation) 
Prof. Dr. Lukas Sommer 
Prof. Dr. Adriano Fontana 
 
Zürich, 2011
   
 
 
  Disclaimer 
 3 
 
Disclaimer 
The thesis was based upon and partly adapted from the following manuscript: 
 
Johannes vom Berg, Sergio Haller, Aladin Haimovici, Paulina Kulig, Silvia Behnke 
and Burkhard Becher:  
Intratumoral application of Interleukin-12 in combination with systemic 
CTLA-4 blockade leads to T-cell dependent rejection of advanced stage 
glioma 
 
  
    
 4 
  Table of Contents 
 5 
Table	  of	  Contents	  
Zusammenfassung	  ...............................................................................	  9	  
Summary	  ...........................................................................................	  11	  
Abbreviations	  ....................................................................................	  13	  
1.	  Introduction	  ..................................................................................	  15	  
1.1 Cancer ................................................................................................................... 15	  
1.1.1 Classical hallmarks of cancer .......................................................................... 15	  
1.1.1.1 Self-sufficiency in growth signals ....................................................................... 15	  
1.1.1.2 Insensitivity to growth-inhibition ........................................................................ 16	  
1.1.1.3 Evasion of programmed cell death (Apoptosis) .................................................. 16	  
1.1.1.4 Limitless replicative potential .............................................................................. 17	  
1.1.1.5 Sustained angiogenesis ........................................................................................ 17	  
1.1.1.6 Tissue invasion and metastasis ............................................................................ 18	  
1.1.2 Revised concepts and new hallmarks ............................................................. 18	  
1.1.2.1 Tumor microenvironment .................................................................................... 18	  
1.1.2.2 Genome instability ............................................................................................... 19	  
1.1.2.3 Altered energy metabolism .................................................................................. 19	  
1.1.2.4 Tumor promoting inflammation and evasion of immune destruction ................. 19	  
1.2 Cancer and the immune system .......................................................................... 21	  
1.2.1 From cancer immunosurveillance to cancer immunoediting .......................... 21	  
1.2.1.1 Elimination ........................................................................................................... 23	  
1.2.1.2 Equilibrium .......................................................................................................... 29	  
1.2.1.3 Escape .................................................................................................................. 30	  
1.2.1.4 Cancer immunoediting in humans ....................................................................... 32	  
1.2.2 Tumor promoting inflammation ..................................................................... 33	  
1.2.3 Immunotherapy ............................................................................................... 34	  
1.3 The Interleukin-12 family cytokines .................................................................. 35	  
1.3.1 Interleukin-12 .................................................................................................. 36	  
1.3.1.1 Interleukin-12 in cancer immunobiology ............................................................ 37	  
1.3.1.2 Interleukin-12 in cancer immunotherapy ............................................................. 39	  
1.3.2 Interleukin-23 .................................................................................................. 40	  
1.3.2.1 Interleukin-23 and cancer .................................................................................... 41	  
1.4 Malignant gliomas ................................................................................................ 43	  
1.4.1 Histological classification and molecular characterization ............................. 43	  
1.4.2 Current glioma therapy ................................................................................... 45	  
1.4.3 Experimental glioblastoma models ................................................................. 46	  
1.4.3.1 Genetic models .................................................................................................... 46	  
1.4.3.2 The C57BL/6 syngeneic glioma cell line Gl261 ................................................. 47	  
   Table of Contents    
 6 
1.4.4 Gliomas, immune privilege and immunosuppression ..................................... 48	  
1.4.5 IL-12 and IL-23 in glioma tumorimmunology ............................................... 48	  
1.4.4 Glioma and immunotherapy ........................................................................... 49	  
1.5 Aims of the study .................................................................................................. 51	  
2	  Results	  ............................................................................................	  53	  
2.1 The effects of IL-12 and IL-23 expression in Gl261 cells ................................. 53	  
2.1.1 Gl261-luc, a cell line suitable for bioluminescent in vivo imaging ................ 53	  
2.1.2 Expression of IL-12 and IL-23 single chain Fc-fusion constructs .................. 53	  
2.1.3 Characterization of IL-12 and IL-23 expressing glioma cells ........................ 55	  
2.1.4 Intratumoral expression of IL-12 but not IL-23 leads to rejection of 
experimental gliomas ............................................................................................... 56	  
2.1.5 Cytokine dependent infiltration of experimental gliomas .............................. 58	  
2.2 Mechanisms of IL-12 mediated rejection of experimental glioma .................. 61	  
2.2.1 T-cells rather than NK-cells are crucial for IL-12 mediated glioma rejection 61	  
2.2.1.1 CD8+ together with CD4+ T-cells mediate IL-12 induced glioma control .......... 61	  
2.2.1.2 Memory formation in surviving Gl261 IL-12 challenged animals ...................... 63	  
2.2.2 Effector molecules of IL-12 mediated glioma rejection ................................. 63	  
2.2.2.1 IFN-γ deficient animals reject Gl261 IL-12 ........................................................ 63	  
2.2.2.2 Perforin, a cytolytic molecule crucial for IL-12 mediated glioma rejection ....... 64	  
2.3 Combination therapy approaches for advanced experimental glioma ........... 65	  
2.3.1 Systemic application of IL-12 combined with CTLA-4 blockade .................. 65	  
2.3.3 Local treatment ............................................................................................... 66	  
2.3.3.1 Purification of IL-12Fc ........................................................................................ 66	  
2.3.3.2 Local treatment directed against advanced glioma .............................................. 67	  
2.3.3.3 Impact of combination treatment - preliminary observations .............................. 69	  
3	  Discussion	  .......................................................................................	  73	  
3.1 Technical considerations ..................................................................................... 73	  
3.1.1 Experimental model ........................................................................................ 73	  
3.1.2 Bioluminescent imaging ................................................................................. 73	  
3.1.3 Expression of luciferase in Gl261 cells .......................................................... 74	  
3.1.4 Cytokine expression vectors ........................................................................... 74	  
3.1.5 Quantitative flow cytometric analysis of tumor invading lymphocytes ......... 74	  
3.2 Mice bearing Gl261 IL-23 show reduced survival compared to controls ....... 75	  
3.3 Effector mechanisms of IL-12 mediated glioma rejection ............................... 76	  
3.3.1 T-cells are the major effector population in IL-12 induced glioma rejection . 76	  
  Table of Contents 
 7 
3.3.2 IL-12 induced glioma rejection in absence of IFN-γ ...................................... 77	  
3.3 Treatment of advanced stage experimental glioma .......................................... 78	  
3.3.1 Efficient tumor rejection after local IL-12 treatment in combination with 
systemic CTLA-4 blockade ..................................................................................... 78	  
3.3.2 A reversal of the GBM induced immunosuppression? ................................... 79	  
3.3.3 Translational potential of combination therapy with local IL-12Fc and 
systemic CTLA-4 blockade ..................................................................................... 80	  
3.4 Concluding remarks and future directions ....................................................... 81	  
4	  Methods	  .........................................................................................	  83	  
4.1 In vivo Manipulations .......................................................................................... 83	  
4.1.1 Animals ........................................................................................................... 83	  
4.1.2 Orthotopic glioma inoculation ........................................................................ 83	  
4.1.3 In vivo bioluminescent imaging ...................................................................... 83	  
4.1.4 Treatment of established gliomas ................................................................... 84	  
4.1.5 Survival analysis of tumor bearing animals .................................................... 84	  
4.2 Cell culture ........................................................................................................... 85	  
4.2.1 Mouse glioma cell lines .................................................................................. 85	  
4.2.2 Proliferation assay ........................................................................................... 85	  
4.2.3 Expression and purification of IL-12Fc .......................................................... 85	  
4.3 Analysis of Tumor infiltrating lymphocytes ...................................................... 86	  
4.3.1 Histology ......................................................................................................... 86	  
4.3.2 Stereometric assessment of tumor volume ..................................................... 86	  
4.3.3 Flow cytometry ............................................................................................... 87	  
4.4 Statistical analysis ................................................................................................ 88	  
References	  ........................................................................................	  89	  
Appendix:	  	  Reducing	  Alzheimer’s	  disease	  β-­‐amyloid	  by	  manipulating	  IL-­‐
12/IL-­‐23	  signaling	  .............................................................................	  107	  
Acknowledgements	  ..........................................................................	  133	  
 
 
  8 
 
  
  Zusammenfassung 
 9 
Zusammenfassung 
Glioblastome (Glioblastoma multiforme, GBM) sind extrem bösartige primäre 
Hirntumore mit wenigen Behandlungsoptionen und äusserst schlechter Prognose. 
Trotz chirurgischer Resektion und adjuvanter Radio- und Chemotherapie liegt die 
mittlere Lebenserwartung nach Diagnose bei 14-15 Monaten. Glioblastome sind oft 
resistent gegen Strahlen- und Chemotherapie und wachsen sehr infiltrativ. Sie 
induzieren zudem ein stark suppressives, regulatorisches lokales Milieu, um sich der 
Entdeckung und Zerstörung durch das Immunsystem zu entziehen. 
Diese Eigenschaft wird in experimentellen GBM Mausmodellen wie z.B. Gl261 gut 
wiedergegeben. Die lokale Gabe von proinflammatorischen Botenstoffen ist ein 
vielversprechender Ansatz in experimentellen Modellen, um dieses suppressive 
Tumormilieu in eine entzündliche Umgebung zu verwandeln. Obwohl die positive 
Wirkung einer solchen Immuntherapie in frühen GBM Stadien gut dokumentiert ist, 
konnte eine effiziente Behandlung fortgeschrittener GBM Erkrankungen selbst in 
präklinischen Modellen nur selten demonstriert werden. 
Ausgangspunkt der vorliegenden Studie war, die Frage zu beantworten, ob die 
proinflammatorischen Interleukine (IL) -12 und -23 eine gegen GBM gerichtete 
Immunantwort auslösen, wenn sie von murinen GBM Zellen exprimiert werden. Die 
Expression von IL-23 hatte keine Tumorabstossung zur Folge, sondern schien das 
Fortschreiten des Glioblastoms sogar noch zu beschleunigen. Im Gegensatz dazu löste 
IL-12 eine beeindruckende, gegen den Tumor gerichtete Immunantwort aus. Diese 
war von einer verstärkten Infiltration von Immunzellen in das GBM und einem 
Wechsel von einem regulatorischen zu einem entzündlichen Phänotyp derselben 
geprägt. Indem wir die IL-12 induzierte Immunantwort in einer Reihe von Maus-
Mutanten untersuchten, konnten wir eine klare Abhängigkeit dieser Tumorabstossung 
von CD4 und CD8 positiven T-Zellen zeigen. Andererseits schienen Natürliche Killer 
(NK)-Zellen für die IL-12 induzierte, gegen das GBM gerichtete Immunantwort nicht 
unbedingt notwendig zu sein. Um unsere Ergebnisse in einem therapeutischen 
Rahmen zu testen und die Erkenntnis auszunutzen, dass T-Zellen eine wichtige Rolle 
bei der Kontrolle des Tumors spielen, wendeten wir eine Kombinationstherapie gegen 
weit fortgeschrittenes, experimentelles GBM an. Wir untersuchten die Wirkung 
lokaler Applikation von IL-12 in den Tumor zusammen mit systemischer Blockade 
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eines hemmenden Korezeptors auf T-Zellen namens Cytotoxic T-lymphocyte 
Associated Antigen-4 (CTLA-4). Dies führte zu einer fulminanten Immunantwort 
gegen den Tumor und zur Abstossung von bereits weit fortgeschrittenem Gl261 
GBM.  
Unsere Daten stellen eindrucksvolle präklinische Beobachtungen dar, die ein 
unverzügliches Umsetzen in klinische Studien an Patienten mit GBM nahelegen. Die 
Zulassung eines monoklonalen Antikörpers zur Blockade von humanem CTLA-4 für 
die Behandlung von metastasierenden Melanomen durch die amerikanische Food and 
Drug Administration (FDA) zu Beginn dieses Jahres unterstreicht die Aktualität 
unserer Ergebnisse. 
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Summary 
Glioblastoma multiforme (GBM), a highly malignant primary brain cancer, is one of 
the most aggressive tumors known to man. Treatment options are limited and clinical 
prognosis poor. Patients diagnosed with GBM show a median survival of 14-15 
months despite surgical resection, radiation, and chemotherapy. GBM spreads deep 
into the brain parenchyma and is often radio and chemotherapy resistant. Moreover, 
GBM induces a highly suppressive microenvironment to avoid detection and 
destruction by the immune system. This characteristic is well reproduced in 
experimental models of the disease like the murine GBM Gl261. Reversing this 
microenvironment by local application of pro-inflammatory cytokines represents a 
promising therapeutic approach and has led to considerable success in experimental 
models. While successful immunotherapy in early established experimental GBM is 
well documented, efficient treatment of advanced stage GBM has even in preclinical 
models rarely been demonstrated by most therapeutic approaches. We tested the 
ability of two pro-inflammatory cytokines, namely Interleukin-12 (IL-12) and 
Interleukin-23 (IL-23), to elicit an anti-GBM immune response when expressed in 
murine GBM cells. IL-23 expression did not result in tumor rejection, but appeared 
rather to foster tumor growth. In contrast, IL-12 elicited a remarkable anti-tumor 
immune response. This was accompanied by an increase in tumor infiltrating 
lymphocytes and a phenotypic change from regulatory to effector cells. Studying IL-
12 induced tumor rejection in a series of mouse mutants, we observed a crucial 
dependence on CD4+ and CD8+ T-lymphocytes. Natural killer (NK) cells, on the other 
hand, seemed to be expendable. Translating our findings into a therapeutic setting and 
exploiting the observed T-cell dependence, we attempted a combinatorial approach to 
treat advanced stage experimental GBM. To this end, we combined local IL-12 
application into the tumor with systemic blockade of the inhibitory co-receptor 
cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), a treatment that recently 
entered clinical practice. This resulted in a powerful immune response and led to 
eradication of even far progressed Gl261 GBM. Our data provides thus compelling 
preclinical observations to warrant the immediate translation into clinical trials in 
humans. 
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Abbreviations 
5-ALA  5-aminolevulinic acid 
APC  Antigen presenting cells  
ATP  Adenosine 5´-triphosphate  
BLI  Bbio-luminescent imaging 
CED  Convection enhanced delivery 
CNS  Central nervous system 
CTL  Cytotoxic T-Lymphocyte 
CTLA-4  Cytotoxic T-lymphocyte antigen-4  
DC  Dendritic cell 
DMBA  9,10-dimethyl-1,2-benzanthracene 
DTT  Dithiothreitol 
EAE Experimental autoimmune 
encephalomyelitis 
ECM  Extracellular matrix 
EGF  Epidermal growth factor  
FGF1  Acidic fibroblast growth factor  
FGF2  Basic fibroblast growth factor 
GBM  Glioblastoma multiforme 
GM-CSF  Granulocyte Monocyte-colony 
stimulating factor 
HE  Hematoxylin & Eosin 
i.t.  intratumoral 
i.v.   intravenous 
ICOS  Inducible co-stimulator 
IDH-1  Isocitrate dehydrogenase-1 
IDO  Indoleamine 2,3-dioxygenase 
IFN-γ  Interferon-γ 
IgG3  Immunoglobulin-G3 
IL  Interleukin 
IP-10  Interferon-inducible protein 10 
JAK  Janus kinase 
kDa  Kilo Dalton 
KIR  Killer Cell Immunoglobulin like 
Receptors 
LPS  Lipopolysaccharide 
LT  Lymphotoxin 
MCA  3-Methylcholantrene 
MDSC  Myeloid-derived suppressor cells 
MHC  Major histocompatibility complex 
MIC A  MHCI polypeptide-related sequence A 
MIG  Monokine induced by gamma interferon  
MMP  Matrix metalloprotease 
MNU  N-methyl-N-nitrosourea 
MRI  Magnetic resonance imaging 
MTD  Maximal tolerated dose 
NF-1  Neurofibromatosis-1 
NF-κB  Nuclear factor-κB 
NK-cell  Natural killer cell  
NKG2D  Natural killer group2 receptor, member D  
NKT-cell  Natural killer T-cell 
PAGE  Poly acrylamide gel electrophoresis 
PAMP  Pathogen associated molecular pattern 
PBS  Phosphate buffered saline 
PD-L1  Programmed death ligand-1 
PDGF  Platelet derived growth factor 
PET  Positron emission tomography 
PGE2  Prostaglandin-E2 
PI(3)K  Phosphatidylinositol-3-OH kinase 
pRb  Retinoblastoma protein 
PTEN  Phosphatase and tensin homolog 
RAE1  Retinoid acid early-inducible protein 1 
RAG  Recombination activating gene 
ROI  Region of interest 
ROS  Reactive oxygen species 
RT-PCR  Reverse transcriptase-Polymerase chain 
reaction  
s.c.  subcutaneous 
SDS  Sodium dodecyl sulphate- 
STAT  Signal transducer and activator of 
transcription 
TAA  Tumor associated antigen 
TAM  Tumor associated macrophage   
TCR  T-cell receptor 
TGF-α  Transforming growth factor-α 
TGF-β  Transforming growth factor-β 
TIL  Tumor infiltrating lymphocyte 
TLR Toll like receptor 
TNFR  Tumor necrosis factor receptor 
TPA  12-O-tetradecanoyl-phorbol acetate 
TH  T-helper cell 
Treg  Regulatory T-cell  
UTR  Untranslated region 
VEGF  Vascular endothelial growth factor 
wt  wild-type 
αGalCer  α-Galactosylceramide
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1. Introduction 
1.1 Cancer 
The advance of medicine over the last centuries has made infectious diseases less 
frightening to economically developed countries. However, increasing age, physical 
inactivity, smoking and dietary changes make cancer the leading cause of death in 
these countries7. “If we lived long enough, sooner or later we all would get cancer”8 
says Robert A. Weinberg, cancer researcher at the Massachusetts Institute of 
Technology. A malignant tumor, showing uncontrolled and invasive growth of cells 
that used to be a functional, integral part of an organ is only the clinically apparent 
late stage of various changes in the genome and metabolism of a cell. Those changes 
accumulate over time as a result of genetic mutations. In a process comparable to 
Darwinian evolution cells are being shaped to possess the ability to overcome the 
complex regulatory circuitry that governs life and death of a single cell. Even though 
appearing to be a disease of the modern times, cancer has always been a part of 
complex organisms like humans. With increasing life expectancy also the likelihood 
increases that cells adopt mutations that lead to Douglas Hanahans´ and Robert A. 
Weinbergs hallmarks of cancer9. These will allow a mutated cell to circumvent the 
control systems of the body. 
1.1.1 Classical hallmarks of cancer 
A single mutation in a cell´s genome is not enough to transform it into a tumor cell. 
Data collected from human and animal studies suggests the requirement of a multi-
step process involving repeated rounds of proliferation and acquisition of further 
mutations that finally lead to malignancy. These mutations result in alterations 
affecting essential aspects of a cells´ physiology. In the following section, these 
hallmark alterations will be shortly mentioned rather than introduced in detail. 
1.1.1.1 Self-sufficiency in growth signals  
In order to enter the cell cycle and to proliferate, cells require an adequate growth 
stimulus. These mitogenic growth signals can be diffusible molecules, extracellular 
matrix (ECM) components or cell-to-cell adhesion/interaction molecules. Various 
alterations can lead to an autonomy of these signals: cells may start to secrete the 
growth factors they depend on themselves or stimulate a neighboring cell within their 
Introduction  Hallmarks of Cancer 
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microenvironment to provide them, thereby creating a positive stimulation loop. Also, 
receptors can be over-expressed above physiological levels or truncated in a way that 
regulatory elements are missing. Subsequently minute amounts of ligand or no ligand 
at all is sufficient to trigger proliferation10. The epidermal growth factor receptor 
(EGFR) is one of the receptor tyrosine kinases most often mutated11. Another 
frequently observed phenomenon is the constitutive activation of the intracellular 
signal transduction circuitry whilst intact receptor/ligand systems. A central pathway 
affected is the SOS-Ras-Raf-MAPK cascade. Being exceptionally well studied and 
often found in human colon carcinomas, the Ras protein is mutated in roughly a 
quarter of all human tumors including glioblastomas12,13.  
1.1.1.2 Insensitivity to growth-inhibition 
Anti-growth signals ensure homeostasis in healthy tissues by counteracting signals 
that induce proliferation. Similar to growth factors, they can be cell-based, ECM-
bound or soluble. Some of the signaling pathways blocking entry into the proliferative 
phase of the cell cycle is relayed via the retinoblastoma protein (pRb)14. Transforming 
growth factor-β (TGF-β) is a ligand that leads to blockade of pRb phosphorylation 
and subsequent inactivation of E2F transcription factors. These are crucial for 
entering the S-phase of the cell cycle. Loss of a functional TGF-β receptor or 
mutations in downstream signaling molecules make the cell resistant to growth 
inhibition15. Excess of growth promoting signals, metabolic stress (such as hypoxia) 
and DNA-damage lead to a block of cell-cycle progression until conditions normalize 
or damaged DNA has been repaired. These events are mainly sensed by p53, a key 
molecule that can also induce apoptosis in case of extensive damage to DNA. 
1.1.1.3 Evasion of programmed cell death (Apoptosis) 
Similar to proliferation, also cell death is tightly regulated. Apoptosis is a highly 
organized and complex process removing a cell from a given tissue16. The 
extracellular and intracellular environment of a cell inspects the metabolic and genetic 
status of the cell and can induce apoptosis by two main pathways. The extrinsic 
pathway is ligand/receptor dependent, whereas the intrinsic pathway is triggered from 
within the cell and reacts mainly to metabolic stress, including DNA-damage or 
survival factor insufficiency. In addition to these two inducers, immune cells via the 
perforin/granzyme pathway can also trigger apoptosis. All three pathways ultimately 
Introduction  Hallmarks of Cancer 
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lead to the activation of cysteine proteases; first initiator caspases, these then activate 
caspase 3, the executioner caspase. The execution pathway will finally lead to cell 
shrinkage, formation of cytoplasmic blebs and apoptotic bodies, chromatin 
condensation and DNA fragmentation. Remaining debris will be taken up by 
surrounding cells via phagocytosis. An important inducer of apoptosis is p53, one of 
the most commonly affected tumor suppressors and mutated in more than 50% of 
human cancers17. Apart from circumventing the induction of apoptosis, many tumors 
also overexpress endogenous inhibitors of programmed cell death such as members of 
the BCL-2 protein family18. 
1.1.1.4 Limitless replicative potential 
Being independent of signals that induce cell division, insensitive to inhibitory 
signals, and resistant to apoptosis, proliferation without limits should be possible. 
However, somatic cells can only divide a certain number of times because of telomere 
shortening. Telomeres are composed of several thousand repeats of short 6 base pair 
(bp) sequence elements at each end of a chromosome. During DNA-replication after 
each cell cycle, 50-100bp of telomeric DNA is lost. This progressive telomere-erosion 
ultimately leads to unprotected chromosomal ends and to karyotypic disarray, 
characterized by end-to-end fusions of chromosomes and results in the death of the 
affected cell19. Most tumors circumvent telomere shortening by expression of the 
enzyme telomerase, which adds the above described hexanucleotide repeats to the 
chromosome ends20,21. With active telomerase a cell can now divide infinitely. 
1.1.1.5 Sustained angiogenesis 
A continuously growing mass of cells quickly reaches a size where local diffusion of 
oxygen and nutrients from the surrounding vasculature will not reach its center. 
During organogenesis vasculature and parenchyma grow in a tightly coordinated 
fashion and thus supply of nutrients and oxygen is ensured. In contrast to that a 
growing tumor soon has to attract and induce its own blood supply in order to 
progress to a clinically apparent malignancy. The induction of a pro-angiogenic 
environment including reduction of signaling molecules that inhibit vessel growth and 
sprouting and an increase in inducers of angiogenesis is called angiogenic switch22,23. 
Among the many pro-angiogenic molecules expressed by tumors are vascular 
endothelial growth factor (VEGF) and acidic and basic fibroblast growth factor 
(FGF1/2). 
Introduction  Hallmarks of Cancer 
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1.1.1.6 Tissue invasion and metastasis 
A malignant tumor invades the surrounding tissue and spreads to distant sites of the 
body. This distinguishes it from a benign tumor, which remains at the site of origin 
and is well separated from the surrounding tissue. Metastases account for 90% of all 
cancer deaths24. Tissue invasion and metastasis is a rather late event in the multi-step 
process of tumorigenesis. Therefore all five traits mentioned above are essential to 
metastasize, a process that can be roughly divided in two steps: translocation from the 
primary tumor to a distant organ and colonization and survival at the secondary site, 
which may represent an entirely different growth-factor and ECM-environment25.  
1.1.2 Revised concepts and new hallmarks 
Taking recent discoveries made over the last decade into consideration, Douglas 
Hanahan and Robert A. Weinstein revised their original six hallmarks of cancer and 
added new concepts4. While the “classical” hallmarks did not lose any of their central 
importance and more molecular players have been added to the existing concepts, it 
has become increasingly clear that the single hallmarks described above are tightly 
interconnected. Moreover, additional cellular and molecular players seem to 
contribute to the emergence of cancer.  
1.1.2.1 Tumor microenvironment 
Already in 2000 it was known that not only the actual cancer cells, but also various 
non-cancer cells found within the bulk tumor contribute to tumorigenesis. These can 
be cancer-associated fibroblasts, endothelial cells, pericytes, bone marrow derived 
stem cells or progenitors, and immune cells (Fig 1). Moreover, this microenvironment 
is changing during different stages of tumor growth. Apart from regular cancer cells 
and invasive cancer cells about to metastasize, a new entity has been described: the 
cancer stem cell (CSC). Originally described in leukemia26, CSC have also been 
described in solid tumors including glioblastomas27. Compared to regular cancer cells 
that are most likely progeny of the CSC, they are rare and slow cycling. Extremely 
low numbers of human CSCs can give rise to new tumors when transplanted into 
immunodeficient mice. Apart from their seeding capacity, CSC have been shown to 
be more radio- and chemotherapy resistant than normal cancer cells, which could 
explain the recurrence of many tumors after initial treatment success28.  
Introduction  Hallmarks of Cancer 
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1.1.2.2 Genome instability 
There is evidence that the accumulation of mutations in cancer cells is not only at the 
very beginning of tumorigenesis, but that genome instability is actually 
instrumentalized to quickly adapt during certain stages of malignant transformation29. 
Telomerase for example is not always expressed at levels that prohibit karyotypic 
disarray. Once mutations acquired this way provide a selective advantage, telomerase 
activity is restored and the new traits are conserved30.  
1.1.2.3 Altered energy metabolism 
Efficient glucose catabolism to pyruvate and subsequently to carbon dioxide crucially 
depends on a sufficient supply of oxygen. Oxidative phosphorylation yields almost 
20-fold more adenosine 5´-triphosphate (ATP), the cell´s energy source, than 
glycolysis. Still, glycolysis is the prevailing mode of energy metabolism in most 
tumors. Consequently, tumors take up more glucose than most surrounding tissues, 
which can be visualized using positron emission tomography (PET). The anaerobic 
environment often found within tumors is likely to be one reason for this metabolic 
switch which is called Warburg effect31. Another explanation would be that within 
tumors the products of glycolysis are used to increase the synthesis of biomolecules 
like amino acids and nucleosides, satisfying the increased demand in fast growing 
cancer tissue32. 
1.1.2.4 Tumor promoting inflammation and evasion of immune destruction 
Emerging tumor nodules are accompanied by immune cells secreting factors that 
contribute to hallmarks like sustained growth, angiogenesis, evasion of cell death and 
ECM remodeling, thus facilitating further progression and metastatic spreading. On 
the other hand – representing “altered self”-tissue for the immune system – tumors 
need to circumvent immune destruction. These two hallmarks will be discussed in 
detail in the section below. Figure 1 outlines the hallmarks of cancer as they are 
conceived in the latest review article by Hanahan and Weinberg4. 
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Figure 1: Hallmarks of cancer and the tumor microenvironment Malignant tumors have 
overcome cell intrinsic suppressors of cancerogenesis such as apoptosis, scarcity of growth 
stimuli, anti-proliferative signaling, DNA-repair mechanisms and telomere shortening. The 
induction of angiogenesis, tissue remodeling leading to metastasis, evasion of an anti-tumor 
immune-response as well as the induction of tumor promoting inflammation involve cell types 
other than the cancer cell itself and are referred to as cell extrinsic hallmarks of cancer. The 
tumor microenvironment comprises the cancer cells themselves including invasive cells and 
cancer stem cells. In addition, endothelial cells, pericytes, fibroblasts, stromal cells as well as 
various immune inflammatory cells contribute to the malignant outgrowth. Adapted from4.   
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1.2 Cancer and the immune system 
1.2.1 From cancer immunosurveillance to cancer immunoediting  
Over one century ago, the chemist and medical scientist Paul Ehrlich already 
suggested that the immune system not only counteracts exogenous pathogens, but also 
limits the number of neoplastic malignancies33. At that time this hypothesis was 
difficult to approach experimentally and not further pursued. In the late 1950s, when 
allograft rejection was attributed to cellular components that recognize distinctive 
structures on cells and first inbred mouse-strains were available, Paul Ehrlich´s 
concept was formally re-introduced as “cancer immunosurveillance“ by Sir 
MacFarlane Burnet and Lewis Thomas34,35. Emerging cancer cells were postulated to 
exert features that render them being detected and eradicated by the immune system, 
leading to their eradication. One direct implication of the surveillance hypothesis is 
that immunosuppressed individuals would show increased incidence of spontaneous 
or induced tumors. Studies aimed at proving this hypothesis yielded contradictory and 
inconclusive results. Especially lack of well-defined and fully penetrant 
immunodeficiencies confounded experiments at this time (reviewed in36). With the 
advance in transgenic mouse technology and availability of specific monoclonal 
antibodies, defined immunodeficiencies had become available in the 1990s. Ensuing 
studies revitalized and ultimately validated the cancer immunosurveillance concept 
(reviewed in37). 
As Paul Ehrlich has envisioned, the immune system seems to prevent the formation of 
cancer in most cases. However, the existence of clinically overt cancer despite this 
surveillance shows that the interaction between tumors and the immune system is 
more complex than initially conceived. There is a growing consensus that the 
relationship between the immune system and cancer has more dimensions than just 
immunosurveillance3,38. Apart from eliminating cancer cells, immunity also sculpts 
the immunogenic phenotype of tumors to evade immune control. Analogous to 
Darwinian evolution, the immune system exerts selection pressure on the rapidly 
mutating, heterogeneous and genetically unstable tumor mass to develop variants with 
reduced immunogenicity to escape immunologic detection and destruction. This 
process is called “immunoediting” and comprises three phases: elimination (also 
known as immunosurveillance or protection), equilibrium (persistence) and escape 
(progression)3,36-39 (Fig 2).  
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Figure 2: Cancer Immunoediting is divided in three phases, Elimination, Equilibrium 
and Evasion Elimination: Transformed cells are detected by the innate and adaptive immune 
system sensing stress signals, killer-receptor ligands and the presence of tumor associated 
antigens (TAAs). This leads to elimination of the nascent tumor before it reaches clinically 
apparent stages. In the equilibrium phase tumor cells that were not deleted are merely hold in 
check by the immune system. The genetically unstable tumor mass is being selected to 
develop less immunogenic variants and induce an immunosuppressive tumor promoting 
microenvironment. Just like the elimination phase, the equilibrium phase is clinically not 
apparent and can last many years. Escape: The tumor has evolved into a non-immunogenic, 
highly immunosuppressive malignancy that attracts various innate and adaptive immune cells 
fostering invasive growth and maintaining a permissive environment while suppressing 
effector T-cell and CTL function3.     
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1.2.1.1 Elimination 
In case cell intrinsic tumor suppressors like DNA-repair mechanisms, apoptosis and 
growth-factor restriction are overcome, cell extrinsic tumor suppressors, i.e. the 
immune system can prevent tumor growth by eliminating nascent tumor cells. So far, 
the elimination phase has only been observed indirectly in vivo. However, many 
studies have shown that various signaling and effector molecules as well as cellular 
components of the innate and the adaptive immune system play an essential role 
during elimination. For instance, immunodeficient mice show enhanced susceptibility 
to chemical carcinogenesis as well as spontaneous tumors (reviewed in38 and40). The 
mechanisms that lead to the activation of the immune system are not yet completely 
understood. Among the various triggers conceivable are tissue destruction during 
invasion and release of antigens during tumor cell necrosis due to hypoxia or genome 
instability4,41, as well as oncogene-induced expression of stress-ligands42. Innate 
immune cells such as natural killer cells (NK-cells), natural killer T-cells (NKT-cells), 
gamma delta T-cells (γδ T-cells) as well as macrophages (Mϕ) and certain dendritic 
cells (DCs) are among the first cells attracted by cancerous lesions and comprise the 
first line of defense against tumors. Subsequently, cells of the adaptive immune 
system will launch a more specific attack directed against altered components of the 
malignant cell (Fig 2). 
1.2.1.1.1 Natural killer cells 
NK-cells are considered to be part of the innate immune system, even though recent 
publications point out similarities to cytotoxic T-lymphocytes (CTLs) in their genesis 
and homeostasis (reviewed in43). NK-cells bear a variable set of activating and 
inhibitory receptors and are able to directly induce apoptosis in their targets. They are 
mainly directed against transformed cells, cells that are experiencing unphysiologic 
levels of stress or cells that are infected with intracellular pathogens such as viruses. 
Upon interaction with the target cell, granules containing perforin and granzyme 
release their content. Perforin creates pores in the plasma membrane of the target cell, 
granzymes enter the cell and cleave precursors of caspases leading to apoptosis of the 
target cell. Moreover, NK-cells can activate other immune cells through secretion of 
Interferon-γ (IFN-γ) and other cytokines. One of the activating receptors is the natural 
killer group2, member D (NKG2D), which binds to ligands expressed on the surface 
of stressed cells. Examples for these ligands are the retinoid acid early-inducible 
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protein 1 (RAE1, murine) or MHC-class-I-polypeptide-related sequence A (MICA, 
human). The expression of both is upregulated in response to chronic activation of the 
DNA-damage response pathway due to cell intrinsic tumor suppressor mechanisms44. 
On the other hand, members of the Killer Cell Immunoglobulin like Receptors (KIR) 
family in humans and the C-type lectin-like Ly49 receptors in mice bind to Major 
Histocompatibility Complex class I molecules (MHCI) on healthy cells and inhibit 
NK-cell activation45. In the course of viral infections or malignant transformation, 
surface MHCI expression can be reduced, lost or altered, to reduce the presentation of 
altered “self”-peptides to CTLs. Therefore NK-activating signals will prevail. This 
mechanism of surveillance for the expression of MHCI and activation of NK-cells is 
formulated in the “missing-self hypothesis”46. NK-cells critically depend on 
Interleukin-15 for their development47. Antibody mediated depletion of NK-cells or 
genetic deficiency in perforin leads to increased incidence of 3-methylcholanthrene 
(MCA) induced sarcomas and spontaneous lymphoma in mice48,49. 
1.2.1.1.2 Natural Killer T-cells 
Natural Killer T-cells (NKT-cells) belong to the family of innate-like lymphocytes 
sharing features of NK-cells and T-cells. On the one hand they express functional 
NK-cell receptors such as NK1.1 (murine, C57BL/6), on the other hand they express 
a functional αβ T-cell receptor (TCR). However, unlike αβ T-cells, they recognize 
antigens presented in the context of the non-classical MHC-like molecule CD1d, 
which preferentially presents glycolipids. Upon stimulation, NKT-cells can directly 
lyse target cells in a perforin-dependent manner. More importantly, they can release 
copious amounts of Interleukin (IL) -4, IL-10, IL-13 as well as IFN-γ and tumor 
necrosis factor alpha (TNFα), thereby polarizing immune responses towards TH1 or 
TH2 conditions. For the elimination phase during tumor immunosurveillance 
especially the type I NKT-cells seem to play a role. These express the unique TCR 
Vα14Jα18 (mouse) or Vα24Jα18 (human) paired with a limited selection of Vβ chains 
and recognize the glycolipid α-galactosylceramide (αGalCer)50. Mice lacking this 
subtype of NKT-cells (Jα18-/-) have a higher incidence of MCA-induced 
sarcomas51,52. Their ability to rapidly produce IFN-γ to recruit NK-cells and CD8+ T-
cells and to polarize DCs seems to be more important than direct lysis of tumor 
cells53. 
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1.2.1.1.3 Gamma delta T-cells 
A minority of T-cells does not use the α- and β- chain but recombines the γδ-
segments of the T-cell receptor (TCR) locus. Most of them are CD4 and CD8 
negative and do not recognize peptides presented in the context of MHC. The γδ-TCR 
shares similarity with immunoglobulin heavy chains in that they vary in length; while 
only few γδ combinations have been described, it is likely that the unique mode of 
antigen recognition compensates for the limited number of γδ combinations. Just as 
NK-cells and NKT-cells, some γδ T-cell subsets express the activating receptor 
NKG2D. Most γδ T-cells are found in the skin, the gut and the genitourinary tract. 
Upon recognition of stressed or transformed cells, γδ T-cells can respond with 
secretion of TH1 cytokines and perforin/granzyme mediated lysis of target cells54,55. 
Tcr δ-/- mice lacking γδ T-cells develop squamous-cell carcinoma upon MCA 
treatment with shorter latency and in higher number than control animals and the 
malignant progression from papilloma to carcinoma is accelerated56.  
1.2.1.1.4 Macrophages 
Macrophages can make up a substantial proportion of a tumor´s cell mass. Their main 
function is phagocytosis of dead cells, debris and microbial pathogens. Being 
activated by pathogen associated molecular patterns (PAMPs) such as 
lipopolysaccharides (LPS), cell debris following necrosis (as found in unstable tumor 
masses), or by cytokines such as IFN-γ, they adopt the M1-phenotype. M1 
macrophages are characterized by production of proinflammatory cytokines such as 
IL-12, IL-1β, IL-6 and TNF-α, tumoricidal reactive oxygen and nitrogen species, and 
efficiently induce TH1 responses57,58. However, in the course of tumorigenesis, 
macrophages often adopt an M2-phenotype that is tumor promoting and rather leads 
to immune-evasion. This will be discussed below. 
1.2.1.1.5 Dendritic Cells 
DCs are another member of the innate immune system and essential for adaptive 
immunity as they are the main antigen presenting cells (APCs) for T-cells. Moreover, 
DCs not only provide processed antigens loaded as peptides on MHC class-I or -II 
molecules and activate naïve T-cells by providing co-stimulatory signals, but also 
influence the nature of the T-cell response with additional instructive signals using 
cytokines. There exist many different subclasses of DCs with a high degree of sub 
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specification of their function during an immune response. Even though there is a 
certain subset described that is able to recognize and kill tumor cells directly via 
perforin/granzyme59, the main function of DCs during elimination is probably the 
induction to of an adaptive anti-tumor response. Transformed cells detected by the 
expression of oncogene induced stress ligands such as RAE1 are lysed directly by 
innate immune cells (NK-cells, NKT-cells, γδ-T-cells) or undergo necrotic death 
because of the antitumor effect of reactive oxygen or nitrogen species and IFN-γ36. 
IFN-γ may increase immunogenicity of tumor cells by upregulation of MHC class-I, 
inhibit angiogenesis and induce apoptosis37. Necrosis and apoptosis of tumor cells 
liberates antigens that are being processed and presented to naïve T-cells by DCs and 
thus an adaptive immune response can be initiated.   
1.2.1.1.6 T-lymphocytes 
The adaptive immune system consists of B-cells, representing the humoral branch and 
T-cells, representing the cellular branch. Originating from bone marrow precursors, 
conventional T-cells rearrange the α- and β-chain segments of the TCR gene locus 
during their maturation in the thymus. This recombination is dependent on the product 
of the recombination activating genes (RAG) 1 and 2. Consequently, Rag1-/- and 
Rag2-/- mice lack all T-lymphocytes including NKT-cells and γδ-T-cells as well as B-
cells60,61. Conventional T-cells can be distinguished into two groups: CD4+ TH cells 
recognize antigen presented on MHC class-II molecules and CD8+ cytotoxic T-
lymphocytes (CTLs) recognize their cognate antigen on MHC class-I molecules. All 
cells of the body – with few exceptions such as mature erythrocytes – express MHCI. 
CTLs constantly screen the organism for signs of intracellular pathogens or 
transformation. In case of transformed cells these signs can be neo-antigens resulting 
from mutations in protein coding genes as well as quantitative differences in 
expression. CTLs can induce apoptosis of their target by various mechanisms:  
i) Expression of Fas-ligand, which binds to Fas (CD95) on the surface of the 
target cell. Activation of Fas triggers the classical pathway of apoptosis.  
ii) Secretion of lytic granules containing perforin and granzyme.  
iii) Secretion of TNF-α, which binds to the Tumor necrosis factor receptor 
(TNFR) and also induces apoptosis. CTLs also secrete copious amounts of 
IFN-γ, which in turn increases expression of MHC class-I and Fas, 
increasing altered-self peptide presentation and susceptibility to Fas-ligand 
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induced caspase activation on respective target cells62.  
Compared to CTLs, TH cells show a greater diversification. Upon activation, a naïve 
CD4+ T-cell will differentiate into various subsets with distinct properties (reviewed 
in63): TH1 cells secrete IFN-γ and IL-2 and express the transcription factor T-bet. 
They induce and maintain an M1 phenotype in macrophages and induce reactive 
oxygen species (ROS) and TNF-α production. TH1 derived IL-2 can provide an 
additional activation stimulus for CTLs. TH1 cells are the main drivers of cellular 
immunity against intracellular pathogens. Conversely, TH2 cells mainly produce IL-4, 
IL-5, IL-10 and IL-13; they express the transcription factor GATA3, counteract TH1 
polarization and play a key role in humoral immunity. More recently discovered TH17 
cells, characterized by the expression of IL-17 and the transcription factor RORγt, 
seem to be implicated in mucosal immunity and a variety of autoimmune diseases. 
Regulatory T-cells (Tregs) secrete TGF-β and IL-10, express the transcription factor 
FoxP3, (down-) regulate immune responses and maintain self-tolerance. The 
activation and polarization of naïve T-cells is tightly regulated by APCs such as DCs 
and macrophages by a set of three independent signals:  
i) Cognate peptides loaded onto MHC molecules, bound by the TCR  
ii) Costimulatory molecules like CD80/CD86 expressed on the APC that bind 
to CD28 on the T-cell  
iii) Cytokines that polarize the naïve T-cell into a distinct subset. For example, 
APC-derived IL-12 and IFN-γ lead to a TH1 phenotype while IL-4 drives 
TH2 differentiation.  
Once activated, T-cells down-regulate CD28 and express co-inhibitory receptors such 
as cytotoxic T-lymphocyte antigen-4 (CTLA-4) that also binds CD80/86 but with a 
higher affinity than CD28. It relays an inhibitory signal to prevent overshooting 
immune reactions64. Conversely, CTLA-4 controls Treg function and is constitutively 
expressed in this subset65,66. In the context of tumor elimination, various studies have 
reported increased incidence of spontaneous or chemically induced tumors in RAG1 
or 2 deficient animals lacking B-cells, T-cells, NKT-cells and γδ T-cells (reviewed 
in39).  More specifically, Nishimura and colleagues reported that TH1 cells induced a 
strong cellular immune response leading to clearance of transplanted tumors, while 
TH2 cells induced local inflammatory responses that lead to necrosis67. In adoptive 
transfer studies, both CD4+ and CD8+ cells have been shown to be sufficient for 
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tumor clearance68,69. Even CD4+ cytolytic T-cells have been described when tumor 
specific CD4+ were transferred into lymphopenic hosts70. Nevertheless, in most cases 
efficient tumor eradication requires both cell-types71,72. T-cells distinguish tumor cells 
from normal untransformed cells by detecting tumor-associated antigens (TAAs). 
Since the first identification of a cancer antigen73, a vast number of TAAs have been 
discovered that are mainly recognized by CTLs: Differentiation antigens (e.g. Melan-
A/MART-1 and tyrosinase), mutational antigens (e.g. abnormal forms of p53), 
overexpressed /amplified antigens (e.g. HER-2/neu), viral antigens (e.g. EBV and 
HPV derived) and Cancer-Testis (CT) antigens (e.g.MAGE, BAGE, GAGE)74,75.  
 
In conclusion, both the innate and the adaptive immune system is critically involved 
in the elimination of transformed cells once cell intrinsic tumor suppressor 
mechanisms have been overcome (Fig 2). Only in case of an unsuccessful tumor 
clearance the next two phases apply. 
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1.2.1.2 Equilibrium 
This immune-mediated latency phase is characterized by tumor dormancy and a 
selection process that can take up to decades in humans. Even though the nascent 
tumor is not eradicated, the immune system exerts enough pressure on the 
transformed cells to avoid further malignant progression. However, the genomic 
instability of the cancer cells leads to new mutations that eventually can produce cell 
variants that escape immune control and form clinically apparent malignancies (Fig 
2). Koebel and colleagues could show that unlike in the elimination phase, only the 
adaptive immune system plays a crucial role in the equilibrium phase. Mice treated 
with low doses of the carcinogen MCA showed only small stable masses in some 
cases. When CD4+ T-cells and/or CD8+ T-cells were depleted or IFN-γ or IL-12 were 
neutralized 200 days after MCA treatment, dormant sarcomas started to grow 
progressively. This was not the case when various parts of the innate immune system 
were depleted or neutralized76. Once a dormant tumor has accumulated enough 
mutations or adaptive immunity of the host is severely compromised (as 
experimentally induced in the above experiment), the tumor is able to escape the 
immune system.   
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1.2.1.3 Escape 
The escape phase of cancer immunoediting is always clinically apparent since it leads 
to a rapid progression of tumors. It is characterized by the presence of tumor variants 
that escape immune detection, are resistant to immune-mediated killing and/or that 
are able to induce an immunosuppressive microenvironment tolerating or even 
fostering tumor growth39,77. Overcoming immunosurveillance by escape is one of the 
hallmarks of cancer (Figs 1 and 2).   
1.2.1.3.1 Cell intrinsic mechanisms 
A number of alterations in the tumor cell itself can reduce the chance of detection and 
destruction by the immune system. Selected tumor cell variants may avoid immune 
recognition by interfering with antigen presentation via down-regulation or loss of 
MHCI expression, blocking the antigen processing and loading machinery or by 
becoming insensitive to IFN-γ78,79. Moreover, since the immune system negatively 
selects against specific tumor antigens, variants not expressing these antigens will 
prevail80. In a similar fashion, cells may loose the expression of ligands for activating 
NK-cell receptors such as NKG2D to escape detection of the innate immune system81. 
Another important cell intrinsic alteration is the resistance to apoptosis, a classical 
hallmark of cancer. Not only anti-apoptotic molecules such as members of the Bcl-2 
family, which protect against intrinsic induction of apoptosis, but also expression of 
mutated inactive death receptors such as Fas are frequently found in progressively 
growing tumors82,83. In addition to being resistant to extrinsic induction of apoptosis, 
expression of inhibitory ligands such as programmed death ligand-1 (PD-L1) may 
directly dampen cytotoxicity of T-cells and even induce apoptosis in them84. Also a 
direct “counterattack” by expression of Fas-ligand on tumor cells to induce apoptosis 
in Fas expressing T-cells has been reported85,86.  
1.2.1.3.2 Establishment of an immunosuppressive environment 
Apart from cell intrinsic mechanisms and alterations involving direct juxtacrine 
signaling, tumors establish a local immunosuppressive environment that prevents a 
protective anti-tumor response despite systemic immunocompetence87. Tumor derived 
immunosuppression is achieved by secretion of immunosuppressive soluble mediators 
as well as by attraction of regulatory cells that in turn suppress anti-tumor responses. 
Soluble factors that inhibit the activation of the innate immune system include stress 
induced NKG2D (decoy-) ligands that are shed from the cell membrane and thus 
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interfere with innate recognition of transformed cells88. In addition, the initiation of 
adaptive anti-tumor responses is hindered by manipulation of DCs in their homing to 
draining lymph nodes, antigen uptake and processing thereof. Responsible for these 
effects are a series of tumor derived soluble factors such as sterols and VEGF, the 
latter also leads to increased angiogenesis to overcome shortage of oxygen and 
nutrient supply89-91. One of the most potent anti-inflammatory molecules secreted by 
tumor cells is TGF-β, which suppresses effector T-cells, NK-cells and DCs92. Other 
molecules include cytokines, lectins or enzymes such as IL-10, Galectin or 
Indoleamine 2,3-dioxygenase (IDO), repectively. The IDO-metabolite kynurenin 
inhibits T-cells93-95. Apart from blocking effector function of infiltrating immune 
cells, progressing tumors often attract regulatory and suppressive immune cells. For 
example, accumulating FoxP3+ Tregs secrete TGF-β and IL-10, express CTLA-4 and 
consume IL-296. This results in inhibition of CTLs97. Furthermore, tumor derived 
TGF-β has been shown to convert CD4+ effector T-cells into Tregs. The essential role 
of Tregs in immunoevasion is well documented in experimental tumor models. 
Prophylactic depletion of Tregs, for example, leads to a tumor-eradicating immune 
response98. Not only CD4+ T-cells, but also NKT-cells can obtain a tumor promoting 
regulatory phenotype characterized by the secretion of IL-1396. Various tumor derived 
soluble mediators also attract a heterogeneous group of immature myeloid cells and 
myeloid progenitor cells collectively termed myeloid-derived suppressor cells 
(MDSCs). These mediators are VEGF, IL-1β and Prostaglandin-E2 (PGE2), to name a 
few. MDSCs have been reported to directly suppress effector T-cells, induce Tregs and 
to secrete a number of immunosuppressive molecules including TGF-β99. Another 
myeloid cell type contributes to the immunosuppressive microenvironment: Tumor 
associated macrophages (TAMs). Attracted by IL-4 and IL-13, TAMs are usually M2 
polarized macrophages and mediate suppression by secretion of TGF-β and IL-1057. 
Taken together, the escape phase of cancer immunoediting involves various cell types 
of both adaptive and innate immunity, a fundamental change in the prevalent 
signaling molecules, and is not only dependent on various types of cells attracted to 
the tumor but also on repolarization of inflammatory cells that already reside in the 
vicinity of the tumor. An important prerequisite for the induction of a tumor-
promoting environment and clinically apparent cancer is the acquisition of a set of 
new genetic traits by the cancer cells themselves.   
Introduction  Cancer Immunoediting 
 
 32 
1.2.1.4 Cancer immunoediting in humans 
Despite the fact that most of the experimental data contributing to the formulation of 
the cancer immunoediting hypothesis is derived from studies in mice, there is 
emerging evidence that cancer immunoediting can be applied to human malignancies. 
This evidence can be grouped into three general categories (reviewed in 3,39):  
i) Aquired immunodeficiency or iatrogenic immunosuppression is 
accompanied with a higher risk to develop cancer. Patients with AIDS 
develop virus associated malignancies with higher frequency most likely 
as a result of impaired antiviral immunity, but also types of cancer with no 
known viral etiology such as lung cancer. Also organ-transplant recipients 
receiving immunosuppressive treatment regimens have been reported to 
have a higher risk of developing cancer with known viral etiology as well 
as cancers not associated with viruses, especially UV-induced skin cancer 
and melanomas. 
ii) Spontaneous immune responses in cancer patients involving antibody and 
T-cell responses have been described. Spontaneously regressing melanoma 
lesions were accompanied by clonal expansion of T-cells. Specific CD4+ 
T-cell and CTL responses against TAAs can develop in human cancer 
patients. 
iii) The composition, quantity and localization of tumor infiltrating 
lymphocytes (TILs) correlates with patient survival in various solid 
cancers such as melanoma and ovarian, colon and lung cancer. A low 
amount of Tregs and high proportion of CTLs and IFN-γ producing CD4+ 
T-cells is generally associated with an improved prognosis. 
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1.2.2 Tumor promoting inflammation 
Seemingly contradictory, it is conceivable that both immunosurveillance and tumor 
promoting inflammation exist at the same time. Immune cells are found within any 
neoplastic lesion100 and especially innate immune cells may contribute to many if not 
all of the classical hallmarks of cancer (reviewed in40). For example, TAMs are 
essential for angiogenesis, ECM remodeling and facilitate tumor cell migration and 
metastasis101. It is well established that chronic inflammation precedes many forms of 
non-hereditary cancer102. Dependent on the experimental setting, various 
inflammatory cytokines seem to be able to act in a pro- as well as anti-tumorigenic 
fashion. TNF-α deficient animals show increased incidence of MCA-induced 
sarcomas103, but less tumors when a two-step chemical induction protocol is used. 
Carcinogenesis in wild-type (wt) animals was suggested to be dependent on local 
inflammation, which was reduced in TNF-α deficient animals104. Two transcription 
factors seem to be at the crossroads between inflammation and transformation: 
Nuclear factor-κB (NF-κB) as well as signal transducer and activator of transcription 
(STAT) 3 activate genes driving cell survival, proliferation, angiogenesis, invasion, 
and chemokine and cytokine production. Their (pathological) activation is rarely the 
result of upstream mutations but rather due to (inflammatory) signals from 
neighboring cells within the tumor microenvironment105,106. IL-23 is a pro-
inflammatory cytokine that has been reported to also have pro-tumorigenic 
potential107. Expressed by TAMs in a STAT3 and NF-κB dependent manner, its 
tumor-promoting effect is at least partially attributable to the STAT3 dependent 
induction of TH17 cells and Tregs and to tissue remodeling and induction of 
angiogenesis by TAMs. One of the few exclusively anti-tumorigenic cytokines known 
to date is IL-12, expressed by M1 polarized macrophages and an inducer of TH1 cells. 
The switch from M1 to M2 polarization and from IL-12 to IL-23 production in 
macrophages may be the result of increased free lactate and ATP in the tumor 
microenvironment (which again activates STAT3) as a result of the Warburg effect108. 
To conclude, inflammation contributes to tumorigenesis by facilitating and triggering 
various steps of malignant transformation and promotes various mechanisms 
associated with the escape phase of immunosurveillance. Therefore, the induction of 
tumor promoting inflammation is also considered as a hallmark of cancer (Fig 1).  
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1.2.3 Immunotherapy 
The discovery of the first TAAs in the early 90´s and the reappraisal of the 
immunosurveillance-hypothesis stimulated the idea of eliciting an anti-tumor immune 
response as therapeutic approach against cancer. To date, various passive and active 
vaccination approaches as well as antigen independent strategies have been reported. 
Administration of various monoclonal antibodies directed against TAAs such as 
EGFR (Cetuximab) or Her2/neu (Trastuzumab) is about to become part of clinical 
standard treatment regimens109,110. Even though monoclonal antibodies against TAAs 
have shown clinical efficacy in various studies, they are limited to soluble or surface-
bound TAAs. They are costly and usually have to be repeatedly administered111. As 
CTL and TH1-cell infiltration correlates with survival, passive immunization by 
adoptive transfer of autologous T-cells has been put forward. After priming patients 
with a tumor vaccine, peripheral T-cells or tumor infiltrating lymphocytes (TILs, 
purified from resection material) are harvested, activated ex vivo, expanded and 
retransfused112. This method has been shown to improve clinical outcome, especially 
more recent refined approaches using lentiviral gene transfer of chimeric TCRs to 
create tumor specific T-cells113. Classical active vaccination approaches against tumor 
antigens usually use whole tumor cells. Lysates thereof or peptides can also be loaded 
onto DCs. Moreover, DCs can be ex vivo generated and polarized towards subtypes to 
generate the desired type of immune response (reviewed in114). Active vaccination 
approaches have elicited measurable immune responses with considerable clinical 
benefit, as shown in a number of phase II and III clinical trials. Most vaccination 
approaches rely on co-administration or expression of adjuvants to increase the 
immunogenicity of the vaccine during priming and to boost expansion of effector-
cells. Recent studies mainly used defined adjuvants such as granulocyte-macrophage 
colony stimulating factor (GM-CSF) to enhance immunogenicity115, CTLA-4 
blockade to boost effector T-cell activation  and to suppress Tregs116 or IL -2 to boost 
cytotoxicity of adoptively transferred TILs117. Interestingly, Hodi et al recently 
reported that in metastatic melanoma, CTLA-4 blockade without additional peptide 
vaccination can significantly improve overall survival on its own116. This finding is 
considered as a major breaktrough in immunotherapy. Various studies also tested 
local or systemic administration of proinflammatory cytokines to induce an anti-
tumor response, with IL-12 among them. 
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1.3	  The	  Interleukin-­‐12	  family	  cytokines	  
Interleukin-12 is a pro-inflammatory cytokine originally described to promote the 
activation of NK-cells and polarizes naïve T-cells towards a TH1-phenotype during 
the priming phase of an immune response118,119. Mature, functionally active IL-12 is a 
heterodimeric cytokine of 70 kDa, consisting of a smaller p35 α-subunit with 
homology to type I single-chain cytokines such as IL-6 and the larger β-subunit p40 
which rather resembles the IL-6 receptor α-chain120. Disulfide bonds covalently link 
both subunits. Thus, IL-12 resembles a cytokine linked to its soluble receptor. With 
the discovery of various other heterodimeric cytokines sharing structural domains or 
even subunits of IL-12, IL-12 is now considered as the prototype of a group of 
heterodimeric IL-6 related cytokines called the IL-12 family. With the discovery of 
IL-35 in 2007121,122 the IL-12 family now comprises four cytokines, namely IL-12, 
IL-23, IL-27 and IL-35. On this list IL-35 is the most enigmatic member. Not APCs 
Figure 3: Overview over the Il-12 family members, their respective receptors, major 
signal transmitters and functions on target cells All Il-12 family cytokines are 
heterodimers, composed of an Il-6 related α-chain and a cytokine receptor like β-chain. Upon 
engagement of the specific receptors on T and NK cells, Il-12, Il-23 and Il-27, JAK-STAT 
signaling pathways are triggered that lead to induction of various pro-inflammatory immune 
responses. Whereas Il-23 mainly acts on Th17 cells, Il-12 and Il-27 are required for induction 
and maintenance of Th1 responses. For Il-35 neither receptor molecule(s) nor signaling 
pathways are known. In contrast to the other family members, Il-35 is produced by Treg-cells 
and seems to possess immune suppressing abilities (adapted from5 and6, generously 
provided by S. Haller). 
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but Tregs do express it and it has rather immunosuppressive instead of inflammatory 
effects122,123. Moreover, to date neither the receptors nor the downstream signaling 
pathways engaged by IL-35 are known. All other members of the IL-12 cytokine-
family signal via heterodimeric receptors and activate the JAK/STAT signal 
transduction pathway (Fig 3). While data collected on IL-12 and IL-23 function 
almost exclusively supports their pro-inflammatory properties, IL-27 also seems to be 
able to suppress TH1 and TH2 responses under certain conditions5. There are only few 
reports on anti-tumor activity of IL-27 that describe a role similar to IL-12. However, 
IL-27 and IL-35 will not further be discussed here. 
1.3.1 Interleukin-12 
Both human and murine p35 and p40 subunits of IL-12 are encoded in the genome on 
different chromosomes, and their expression levels are distinctively regulated. 
Various types of cells can express IL-12, mainly professional APCs such as 
macrophages and DCs, but also monocytes, neutrophils, B-cells, microglia and even 
astrocytes124-126. Compared to p40 expression, which is more strictly confined to 
APCs and highly inducible upon activation, p35 expression is ubiquitous at low levels 
and seems to be rate limiting for heterodimer secretion127-129. IL-12 is secreted upon 
encounter of PAMPs present on a great variety of pathogens (ranging from gram-
positive and negative bacteria to viruses and even parasites) that trigger invariant 
innate receptors such as toll like receptors (TLRs). Therefore it acts as an early pro-
inflammatory cytokine in response to many infectious agents125,130. Also T-cells can 
contribute to IL-12 production via CD40L – CD40 interaction with APCs131. Most 
important targets of IL-12 are activated T-cells, NKT-cells and NK-cells. IL-12 
induces proliferation and the expression of cytotoxic mediators such as perforin and 
granzyme B. Moreover, it triggers the production of cytokines, especially IFN-γ, but 
also GM-CSF, TNF-α and IL-2; it drives further production of IL-12 from DCs and 
macrophages in a positive feedback loop. Finally, it polarizes naïve T-cells towards 
an IFNγ-producing TH1 effector cell phenotype and suppresses a TH2 effector cell 
phenotype132. The murine as well as the human IL-12 receptor is a heterodimer 
consisting of the IL-12Rβ1 subunit that binds p40 and the IL-12Rβ2 subunit that 
confers specificity to IL-12p70 by preferential binding to p35. Both subunits show a 
high homology to gp130, the β-chain of the IL-6 receptor. Only co-expression of both 
subunits leads to high affinity binding of IL-12p70. The IL-12Rβ2 subunit contains 
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conserved tyrosine residues in the cytoplasmic part that are absent in IL-12Rβ1 
subunit and thus the former appears to act as the signal-transducing element133. 
Binding of the receptor leads to activation of the JAK-STAT pathway. STAT4 is the 
main signal transducer to activate IL-12 mediated cellular responses134. Underlining 
its key role in inducing the TH1 phenotype, IL-12 induces Il-12Rβ2 expression on T-
cells via IFN-γ and T-bet, thus stabilizing TH1 lineage commitment. IFN-γ in turn 
stimulates further IL-12 production. Not only NK-cells and T-cells express the IL-
12R, but also DCs and macrophages. Moreover, since those cells produce IL-12 in the 
first place, a positive autocrine effect is likely135.  
1.3.1.1 Interleukin-12 in cancer immunobiology 
Together with IFN-γ, IL-12 was among the first signaling molecules implicated in 
cancer-immunosurveillance. By virtue of its pivotal role in inducing TH1 responses 
and increasing cytotoxicity of CTLs, NK-cells and NKT-cells, it is likely that the 
elimination phase of the cancer-immunoediting process is significantly affected by 
loss of IL-12 signaling. However, compared to the vast number of reports on IL-12 
application in experimental tumors, only few studies investigated consequences of a 
loss of IL-12 signaling. Indeed, mice deficient for the p35 subunit are more 
susceptible to N-methyl-N-nitrosourea (MNU)-induced T-cell lymphomas, an effect 
that is dependent on IFN-γ and Lymphotoxin (LT)-β136. Moreover, using Il-12p35-/- 
or Il-12rβ2-/- mice, Langowski et al reported increased papilloma formation following 
a two-step skin-carcinogenesis protocol as well as increased growth of various 
inoculated syngeneic tumor cell lines (B16 melanoma, PDV squamous carcinoma, 
LL/2 lung carcinoma)107. Animals deficient for Il-12Rβ2 also develop spontaneous 
plasmacytomas and lung carcinoma at a higher frequency than wt-controls137. Not 
only the elimination but also the equilibrium phase is dependent on IL-12: As 
mentioned earlier, Koebel and colleagues could demonstrate that antibody mediated 
neutralization of IL-12 leads to a re-emergence of dormant sarcomas76. However, 
many other studies using either IL-12/23p40 or IL-12Rβ1 (Fig 3) deficient animals or 
neutralizing antibodies have to be carefully evaluated in light of recent reports on the 
tumor-promoting nature of IL-23 which will be discussed below. Brunda and 
colleagues were the first group to report anti-tumor and anti-metastatic activity of 
systemically administered Il-12 using various mouse carcinoma and melanoma cell 
lines138. Since then a plethora of studies investigated the mechanisms of IL-12 
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mediated tumor rejection (reviewed in139).  These also include transgenic tumor 
models, such as the expression of Her2/neu in mouse mammary tissue, which leads to 
hyperplasia and finally carcinoma formation. Systemic IL-12 treatment delayed and 
reduced occurrence of mammary carcinoma140. Similar results were obtained in a 
transgenic model for spontaneous tumor formation in the choroid plexus of the 
brain141. In both studies mentioned above IL-12 mediated tumor repression also seems 
to be mediated to some extent by the inhibition of angiogenesis. The anti-angiogenic 
effect of IL-12 seems to be dependent on IFN-γ and the chemokines IP-10 and Mig 
and involves T-cells as well as NK-cells142,143. Apart from carcinogen-induced 
tumorigenesis, the majority of studies utilized transplantable tumor models, one of the 
most widely used is the C57/Bl6 syngeneic B16 melanoma144. It is becoming 
increasingly clear that the mechanisms of IL-12 induced tumor rejection vary 
according to the tissue context: Regarding the early report by Brunda et al, IL-12 
mediated rejection of subcutaneous tumors seems to be rather T-cell dependent. In 
their hands NK-cells appeared to be dispensable in the B16 melanoma model138. In 
contrast, animals that exclusively harbour type I NKT-cells (Vα14Jα18) are able to 
control pulmonary and liver metastases as well as subcutaneous (s.c.) B16 tumors 
when treated with IL-12, suggesting NKT-cells as the major effector of IL-12 
mediated tumor rejection145. However, this finding was challenged by another study 
that reported IL-12 induced control of lung metastases in Rag2-/- mice that are T-, B- 
and NKT-cell deficient. Depletion of NK-cells as well as perforin but not FAS-ligand 
abolished the effect in these mice, suggesting a rather NK-cell mediated 
mechanism146. It appeared that at higher doses, IL-12-induced tumor immunity is 
mediated by NK-cells in a perforin-dependent manner. However, at low doses, IL-12 
does not have anti-tumor activity in NKT cell-deficient TCR Jα281–/– mice, 
suggesting an NKT-cell dependent mechanism147. A report by Park and colleagues 
challenged this notion: Despite the absence of NKT-cells, IL-12 treated mice 
exhibited reduced numbers of liver metastases. Moreover Rag1-/- animals treated with 
NK-cell depleting antibodies were still able to suppress s.c. B16 tumors. An innate 
cell type dependent on signaling via the common γ-chain of the IL-2 receptor was 
suggested to mediate this effect. Recently, we discovered that the IL-12 mediated 
suppression of s.c. melanoma is mediated by a small population of RORγt-dependent 
innate lymphocytes (ILCs) bearing the natural cytotoxicity receptor NKp46. These are 
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absent in Rag2-/- Il2rγ-/- animals and seem to coordinate the IL-12 mediated anti-
tumor response148. Highlighting tissue specific differences in IL-12 mediated 
suppression of tumors, rejection of lung metastases seems to be predominantly NK-
cell dependent, while the immune respone to s.c. tumors appears to be mediated by 
NKp46+ ILCs146-149. This observation can be extended to transplantable models of 
lung and colon carcinoma (M. Eisenring and S. Uster, preliminary data). 
1.3.1.2 Interleukin-12 in cancer immunotherapy 
The finding that exogenously delivered IL-12 mediates the suppression of 
experimental tumors in rodents soon encouraged the translation into clinical trials to 
combat cancer in humans. IL-12 was initially tested as a single anti-cancer-agent and 
delivered intravenously (i.v.). Initial phase-I and -II studies on a mixed cohort of 
patients with advanced stages of melanoma, renal, and colon cancer encountered 
severe toxicity including death of some patients and at best modest clinical responses. 
Organs that are targets of IL-12-induced toxicity include the lymphohematopoietic 
system, intestines, liver and lung. Common adverse events include fever/chills, 
fatigue, nausea, vomiting, headache, anemia, neutropenia, lymphopenia, 
hyperglycemia, thrombocytopenia, and hypoalbuminemia. A transient complete 
response in a patient with melanoma and one partial response in a patient with renal 
cell cancer were documented150,151. IL-12 related toxicity is at least in part due to a 
strong increase in IFN-γ levels152. Similar clinical studies with patients suffering from 
renal cancer and melanoma153 or cervical carcinoma154 again reported unsatisfying 
clinical responses albeit induction of proinflammatory cytokines and cellular immune 
responses against human papilloma virus antigens, respectively. Most successful trials 
with objective response rates between 50-56% in AIDS-related Kaposi´s sarcoma and 
cutaneous T-cell lymphoma relied on s.c. or intralesional delivery of IL-12. Even 
though not free of common adverse events, compared to systemic delivery, this local 
route of delivery was well tolerated155,156.  Most studies combining IL-12 with other 
cytokines, monoclonal antibodies or as adjuvant during active vaccination against 
TAAs in melanoma, relied on systemic delivery and showed minimal efficacy157,158. 
As disappointing as the results of early studies using systemic application were, the 
intralesional application that resulted in the best clinical response so far also 
underlines the biological function of a cytokine (IL-12) as a local, paracrine mediator, 
while systemic delivery ignores this fact159. This paradigm shift led to the 
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development of various local delivery approaches. The local intratumoral (i.t.) 
application can be achieved by viral delivery of vectors carrying the IL-12 gene160, 
conjugation of IL-12 protein to polymers, intratumoral administration of plasmid 
DNA coding for IL-12 or autologous transplantation of ex-vivo transduced fibroblasts 
to produce IL-12159. On this list, intratumoral delivery of plasmid DNA is one of the 
most practicable approaches: When plasmid DNA coding for IL-12 was injected 
intratumorally (i.t.), (three injections per cycle, up to seven cycles) in late stage 
melanoma, 3 out of 9 subjects exhibited a clinical response, with one complete 
remission and 2 patients with a stable disease course161. A larger phase I/IB clinical 
trial confirmed the local effect of IL-12. While the size of treated lesions decreased by 
30%, distant lesions were unaffected162. No IL-12 related adverse events were 
reported. Despite a disappointing start, IL-12 cancer immunotherapy still has to be 
considered as a promising additional local treatment option for a variety of solid 
human cancers. 
1.3.2 Interleukin-23 
Based on an in silico search for additional members of the IL-6 cytokine family, a 
novel protein, p19 was discovered. Similar to p35, p19 was found to be poorly 
secreted and to have no biological activity on its own, but together with p40 it formed 
a new heterodimeric secreted cytokine with functions similar as well as distinct from 
IL-12. This new cytokine was termed IL-23163. IL-23 is mainly produced by APCs 
upon stimulation with TLR2 ligands, CD40 crosslinking, IL-1 or IFN-β164-166. 
Analogous to IL-12, IL-23 signals via a heterodimeric receptor composed of the IL-
12Rβ1 subunit and the unique IL-23R subunit, which shows sequence homology to 
IL-12Rβ2 and gp130167. Similar to IL-12Rβ2, IL-23R also bears highly conserved 
tyrosine residues at its cytoplasmic tail and is thought to be the signal-transducing 
element of the JAK/STAT pathway. However, in contrast to the IL-12 receptor 
complex, signaling via the IL-23 receptor preferentially activates STAT3 instead of 
STAT4. The IL-23 receptor is expressed predominantly on T-cells, but also on NK-
cells and APCs such as macrophages, DCs and microglia167-169. Apart from various 
functions in the mucosal response against fungi and bacteria170-173, the discovery of 
IL-23 helped to explain the discrepancy between experimental results obtained with 
either IL-12p35 or IL-12p40 deficient animals in various experimental settings. For 
example, TH1 cells were thought to be the driving subset for a number of autoimmune 
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disorders including multiple sclerosis and its animal model, experimental autoimmune 
encephalomyelitis (EAE). However, animals deficient in IL-12p35 and therefore 
lacking the main TH1 polarizing cytokine were susceptible to EAE while IL-12p40-/- 
mice were resistant174. Conversely, IL-23p19 deficient animals proved to be resistant 
to EAE induction, suggesting that IL-23 is responsible for EAE susceptibility175. 
Ensuing research established a new subset of TH-cells characterized by the expression 
of IL-17. Rather than for the induction, IL-23 seemed to be more involved in the 
maintenance and expansion of this subset. It was termed TH17 and is mainly 
implicated in autoimmune disorders and mucosal host defense176. Of note, recent 
reports could demonstrate that not IL-17, but GM-CSF appears to be the 
encephalitogenic cytokine induced by IL-23 that is involved in EAE and can also be 
produced by TH17 cells177,178. 
1.3.2.1 Interleukin-23 and cancer 
Since IL-23 had been reported to have similar proinflammatory properties as IL-12, 
its role in tumor immunology was investigated soon after its discovery. Using 
retrovirally transfected B16 melanoma as well as CT26 colon carcinoma lines, Lo et 
al showed potent anti-tumor activity of IL-23 comparable to IL-12179. IL-23 was 
reported to be less dependent on IFN-γ and CD4+ T-cells, but rather on the induction 
of CTLs. Other groups reported similar results in a DC-vaccination setting or with 
transfected bone marrow derived neural stem cells to locally deliver IL-23180,181. In 
contrast, a recent study reported a tumor-promoting role of IL-23. Instead of 
expressing IL-23 in tumor cells Langowski and colleagues differentially blocked IL-
23 or IL-12 signalling during tumor establishment by employing cytokine or receptor 
deficient animals and specific neutralizing antibodies107. Together with a skin 
mutagenesis protocol various transplantable tumors were tested. IL-23 deficient 
tumor-bearing animals exhibited a decreased infiltration of myeloid cells, less matrix 
metalloprotease (MMP) expression and lower blood vessel density and a strong 
reduction of IL-17 mRNA. Another recent study using tumor models mainly 
controlled by NK-cells, suggests that IL-23 suppresses innate immunity and thereby 
acts pro tumorigenic182. While there is increasing consensus on a pro-tumorigenic role 
of IL-23, the exact mechanistic underpinnings for its tumor promoting effects may be 
tumor model and tissue specific and still have to be elucidated40,108. 
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1.4 Malignant gliomas 
While many tumors metastasize to the brain, there are also tumors that arise within 
the CNS from neurons, oligodendrocytes or astrocytes as well as from their 
precursors. Gliomas are the most common primary tumors of the CNS, the majority is 
astrocyte derived. Glioblastoma multiforme (GBM) is the most malignant and 
common astrocytic tumor with an invasive and destructive growth pattern183. In most 
European and North American countries, the incidence is in the range of 3-3.55 new 
cases per 100'000 population per year with Switzerland being slightly above the US 
and European average184,185. Ionizing radiation is the only proven risk factor for 
GBM. The most common symptoms are progressive headaches, seizures and focal 
neurologic deficits. Neuroimaging using MRI is the diagnostic gold-standard185. The 
clinical course of the disease is usually short (less than 3 months in more than 50% of 
cases) and patients diagnosed with GBM (WHO stage IV) show a median survival of 
14-15 months despite aggressive surgery, radiation, and chemotherapy186-188. One 
reason for the failure to stop GBM is the widespread infiltration into healthy tissue 
that makes complete surgical resection virtually impossible189. Neoplastic cells can be 
found centimetres away from the bulk tumor and even in the contralateral hemisphere, 
providing a basis for the nearly inevitable recurrence of GBM185. Moreover, the 
existence of CSCs has been described in GBM190. There is evidence that these cells 
are more radio- and chemotherapy resistant, even though molecular markers that 
would unequivocally define these cells are still a subject of intense debate. These 
traits and the observation that the expression of putative glioma-CSC markers 
increases in recurrent GBM tissue suggest that CSCs are crucially involved in the 
treatment resistance of GBM191,192. 
1.4.1 Histological classification and molecular characterization 
Histological assessment of resection material allows classification and staging of 
gliomas. Based on its origin, the tumor can be classified as astrocytoma (most 
gliomas), oligodendroglioma or oligoastrocytoma according to morphological 
features. Further histological/immunohistochemical staging is performed according to 
a WHO-consensus derived scale of I to IV1,193: Grade I tumors can be cured by 
surgical resection and are biologically benign. Grade II gliomas are not curable by 
surgery anymore because of beginning tissue invasion, but progress slowly. Grade III 
tumors exhibit more histological aberrations and higher proliferation rates than Grade 
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II tumors and have a worse prognosis. Grade IV tumors (GBM) additionally show 
aberrant vascularity, necrosis, edema formation and considerable cellular 
heterogeneity and dedifferentiation, hence the name `multiforme´. GBM is treatment 
refractory and the mean survival is still not much more than a year. This highest of the 
four malignancy grades can either develop de novo as primary GBM, as observed in 
patients mostly above the age of 45, or it can progress over a time frame of several 
years from a grade II astrocytoma over a grade III anaplastic astrocytoma to a 
secondary GBM. Secondary GBM is more common among individuals below the age 
of 45, but only accounts for about 10% of all GBM cases (Fig 4). On a molecular 
level, malignant gliomas show a wide range of aberrations involving many hallmarks 
of cancer. Recently, a large-scale analysis of over 200 human GBM specimens was 
performed within The Cancer Genome Atlas project. Sequence mutations, 
amplifications, DNA-methylation and copy-number alterations were systematically 
analyzed187,194. Corroborating countless earlier studies, also this work found 3 
pathways to be predominantly affected in GBM: i) the RTKs involved in growth 
factor and survival signaling, especially PDGFR, EGFR and Her2, ii) the downstream 
Ras/Raf/phosphatidylinositol-3-OH kinase (PI(3)K) pathways (88% of cases). More 
specifically, tumor suppressors like Phosphatase and tensin homolog (PTEN), a 
Figure 4. Classifications and Characteristics of gliomas survival prognosis, common 
genetic alterations and pathobiology. According to histological criteria gliomas are graded on 
a WHO scale of I to IV. Grade I tumors are benign and can be cured if they can be surgically 
resected. Whereas secondary GBMs progress from lower malignancy grades (II>III>IV) 
accumulating various additional mutations over time, primary GBMs arise de novo. (OE) 
Overexpressed; (amp) amplified; (mut) mutated 1 
and model systems; and the systematic and accurate de-
velopment of small molecule drugs, therapeutic antibod-
ies, and the entirely new class of RNA interference
(RNAi)-based agents.
Classification d grading of glioma
The incidence of primary brain tumors worldwide is ap-
proximately seven per 100,000 individuals per year, ac-
counting for ∼2% of primary tumors and 7% of the years
of life lost from cancer before the age of 70. The common
gliomas affecting the cerebral hemispheres of adults are
termed “diffuse” gliomas due to their propensity to in-
filtrate, early and extensively, throughout the brain pa-
renchyma. These gliomas are classified histologically,
immunohistochemically, and/or ultrastructurally as as-
trocytomas, oligodendrogliomas, or tumors with mor-
phological features of both astrocytes and oligodendro-
cytes, termed oligoastrocytomas. Tumors are then
graded on a WHO consensus-derived scale of I to IV ac-
cording to their degree of malignancy as judged by vari-
ous histological features accompanied by genetic alter-
ations (Fig. 1; Louis et al. 2007). Grade I tumors are bio-
logically benign and can be cured if they can be
surgically resected; grade II tumors are low-grade malig-
nancies that may follow long clinical courses, but early
diffuse infiltration of the surrounding brain renders them
incurable by surgery; grade III tumors exhibit increased
anaplasia and proliferation over grade II tumors and are
more rapidly fatal; grade IV tumors exhibit more ad-
vanced features of malignancy, including vascular pro-
liferation and necrosis, and as they are recalcitrant to
radio/chem therapy they ar gener lly lethal within 12
mo. This review focuses on tumors of the astrocytic se-
ries, emphasizing grade IV GBM.
On the basis of clinical presentation, GBMs have been
further subdivided into the primary or secondary GBM
subtypes. Primary GBMs account fo the great majority
of GBM cases in older patients, while secondary GBMs
are quite rare and tend to occur in patients below the age
of 45 yr. Primary GBM presents in an acute de novo
manner with no evidence of a prior symptoms or ante-
cedent lower grade pathology. In contr st, secondary
GBM derives consistently from the progressive transfor-
mation of lower grade astrocytomas, with ∼70% of grade
II gliomas transforming into grade III/IV disease within
5–10 yr of diagnosis. Remarkably, despite their distinct
clinical histories, primary and secondary GBMs are mor-
phologically and clinically indistinguishable as reflected
by an equally poor prognosis when adjusted for patient
age. However, although these GBM subtypes achieve a
common phenotypic endpoint, recent genomic profiles
have revealed strikingly different transcriptional pat-
terns and recurrent DNA copy number aberrations be-
tween primary and secondary GBM as well as new dis-
ease subclasses within each category (as discussed be-
low; Maher et al. 2006; Phillips et al. 2006). These
molecular distinctions make obvious the need to change
the current standardized clinical management of these
truly distinct diseases toward one of rational application
Figure 1. Chromosomal and genet aberratio s involved in the genesis of glioblastoma. Shown are the relationships between
survival, pathobiology, and the molecular lesi ns that lead t the formati n of primary (de n vo) and secon ary (progressive) glio-
blastomas. Although histologically indistinguishable, these grade IV liomas occur in different age groups and present distinct genetic
alterations affecting similar molecular pathways. For example, inactivation of p53 function occurs due to direct mutation in progres-
sive GBMs or INK4aARF mutation/decrease in expression or MDM2 amplification in de novo GBMs. Similarly, activation of the PI3K
pathway is achieved by several cooperative mechanisms, including EGFR amplification and mutation as well as PTEN mutation,
although underexpression of PTEN in the absence of mutation is frequently seen as well. See the text and Figure 2 for details on the
molecular function of implicated genes. (OE) Overexpressed; (amp) amplified; (mut) mutated.
Furnari et al.
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negative regulator of PI(3)K and neurofibromatosis (NF)-1, a negative regulator of 
Ras are affected iii) the inactivation of the p53 (87% of cases) and pRB (78% of 
cases) tumor-suppressor pathways. A similar large-scale study confirmed these 
results195. Even though the final stage is morphologically and clinically 
indistinguishable, there are genetic differences between primary and secondary GBM. 
An enzyme frequently mutated in the latter is the isocitrate dehydrogenase (IDH)-1195. 
In its mutated form IDH-1 contributes to the induction of hypoxia inducible factor and 
subsequently to glucose transporter induction and VEGF production, linking it to 
angiogenesis and altered energy metabolism hallmarks of cancer196. Similarly, there 
are differences in the loss of O6-methylguanine-DNA methyl-transferase (MGMT) 
expression between primary and secondary GBMs. MGMT removes alkyl groups 
from DNA and loss of expression is usually caused by promoter methylation. While 
75% of secondary GBMs show promotor methylation, this is only the case in 36% of 
primary GBMs185. Compared to the initial malignancy, recurrent GBM shows an 
increase in markers for CSCs, these have been reported to show significantly higher 
MGMT-expression than non-CSCs192. A variety of genes altered in GBM are depicted 
in Figure 4. 
1.4.2 Current glioma therapy 
After diagnosis and subsequent symptomatic treatment, glioma treatment usually 
starts with the surgical debulking. More recent approaches use 5-aminolevulinic acid 
(5-ALA), a compound that elicits synthesis and accumulation of fluorescent 
porphyrins within glioma cells to guide the extent of resection. Compared to 
conventional surgery, this indeed leads to a more complete resection, resulting in an 
improved 6 month progression-free survival, but without change of overall 
survival197. Surgical resection also obtains tissue for detailed histological and 
molecular diagnosis. Moreover, the resection cavity can be used for local treatment 
with wafers enriched with chemotherapeutic agents such as the alkylating agent 
carmustine. On the basis of two successful phase III clinical trials, Gliadel® wafers 
have been FDA approved198. Alternatively, catheters that deliver therapeutic agents 
locally via convection enhanced delivery (CED) have been tested. Unfortunately, 
even though promising in early clinical studies, larger phase III trials were 
unsuccessful199-201. Whether this is due to the infused agent or limited diffusion depth 
has not been completely resolved. Resection is followed by chemotherapy with 
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alkylating agents (usually temozolomide) together with focal fractionated 
radiotherapy202. The assessment of MGMT-promotor methylation is an important 
prognostic tool as this enzyme confers resistance against alkylating chemotherapeutic 
agents203. With standard surgery/radiation/temozolomide treatment, patients with 
MGMT-promotor methylation show a median survival of 2 years. The recent research 
on the molecular characterization of GBM has also spurred the development of a 
myriad of molecular targeted therapies. Nonetheless, most of the newly developed 
drugs did not show any convincing clinical efficacy. Neither the application of 
tyrosine kinase inhibitors nor monoclonal antibodies targeting EGF or PDGF or their 
receptors were successful in clinical trials. The same holds true for agents designed to 
inhibit the intracellular growth signal transduction machinery such as inhibitors of the 
Akt/PI(3)K pathway and many others188. So far the most promising approach is the 
inhibition of angiogenesis using monoclonal antibodies against VEGF. The initial 
success in reducing the tumor size has to be interpreted carefully, though: Even 
though FDA approval was given after encouraging clinical response rates in phase II 
trials, there is no data on the effect on overall survival yet204,205. Unfortunately, once 
the tumor circumvents the inhibition of angiogenesis – as also seen in trials using 
VEGFR inhibitors – it progresses aggressively, is refractory to most other treatments 
and leads to death within few months188,206. This therapy therefore represents a 
valuable additional treatment option that should be carefully considered as it is 
eventually overcome by the glioma. The almost inevitable recurrence of GBM is 
treated with variations of the standard regimen and often with investigational clinical 
protocols such as the ones described above. Actually, more than half of the 
glioblastoma trials listed under http://clinicaltrials.gov, an exhaustive database for 
clinical trials, deal with recurrent GBM. Despite the tremendous efforts in the field to 
improve the existing standard treatment protocols, clinicians are still left with few 
strategies to combat this highly aggressive tumor. 
1.4.3 Experimental glioblastoma models 
1.4.3.1 Genetic models 
With increasing insight into the molecular aberrations found within GBM, mouse 
models have been developed, which recapitulate loss of tumor suppressor function or 
gain of function of various oncogenes. Heterozygous deletion of NF-1 and p53 in 
GFAP positive astrocytes (GFAP-cre+;Nf1+/f;p53+/-) leads to a progressive low-grade  
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to high-grade tumorigenesis resembling the disease course of human secondary GBM 
207. If Pten haploinsufficiency is incorporated into the above model (GFAP-
cre+;Nf1+/f;p53f/-;Pten+/f) malignant gliomas occur with an earlier onset without the 
progression phase, similar to human primary GBM208. Other strategies involve the 
overexpression of oncogenic Ras and Akt mutations in astrocyte precursors209,210. By 
now, there is a considerable number of genetic glioma models available. These are 
especially useful to study the molecular etiology of GBM with special emphasis on 
CSC (reviewed in1,187). 
1.4.3.2 The C57BL/6 syngeneic glioma cell line Gl261 
Apart from xenotranplantation models, that will not be discussed here as they usually 
use immunodeficient hosts and therefore are not suitable for immunologic studies, a 
vast amount of data has been generated using transplantable glioma models. One of 
the most commonly used murine transplantable models is the Gl261 glioma. The 
Gl261 tumor was originally induced by intracranial implantation of MCA-pellets in a 
C57BL/6 mouse211. It was propagated by serial orthotopic transplantion, before a cell 
culture line was established. Gl261 has genetic alterations in the tumor suppressor p53 
as well as in the oncogenes k-Ras and c-Myc212. With an in vitro doubling time of 
about 20 hours, Gl261 cells reach densities of up to 2.5x105c/cm2 without signs of 
contact inhibition or reduced viability. In vivo already 100 cells are sufficient to 
establish an intracranial tumor, injection of 1x105 cells is fatal within 25 days. Gl261 
also forms tumors when injected s.c.148,212,213 Low but detectable levels of MHCI are 
expressed on Gl261 cells, MHCII is absent, but can be induced via IFN-γ212. 
Although closely recapitulating various aspects of its human counterpart, such as 
central necrosis, edema 
formation and aberrant 
vessel formation, the 
Gl261 tumor grows not 
as invasively214 (Fig 5). 
Gl261 is especially 
suited for immunologic 
studies as it is syngeneic 
with the C57Bl/6 mouse 
strain, which is widely 
Figure 5 Human GBM and the Gl261 mouse model a human 
post mortem pathology sample exhibiting central necrosis, 
hemorrhages and widespread infiltration crossing the midline, 
left2. Frontal section of a mouse cerebrum bearing a 35-day 
established Gl261 glioma after injection of 2x104 cells; note the 
central necrosis and the brown F4/80 positive TAMs/microglia 
(brown), right  
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used among immunologists. Therefore a vast number of genetically defined 
immunodeficiencies are available.  
1.4.4 Gliomas, immune privilege and immunosuppression 
The concept of the brain as an immuno-privileged organ suggests that the most vital 
organ of the body should be kept from being harmed by overshooting immune 
reactions. There is weaker cellular infiltration of effector cells and low MHCI 
expression in the brain. Additionally, there are fewer APCs and among those many 
with a rather regulatory phenotype. It is now widely accepted that there are still 
immune responses in the brain as seen in CNS-autoimmunity and in responses against 
viruses or parasites. However, there are limitations and differences compared to 
immune responses in the periphery215. Being clinically apparent tumors that managed 
to evade the immune system, gliomas induce a highly immunosuppressive 
microenvironment, which is characterized by the secretion of various 
immunosuppressive cytokines such as TGF-β216, IL-10217, Prostaglandin E2218, 
VEGF219 and others. Moreover, MDSCs and TAMs can be found within the glioma 
microenvironment220,221. As a consequence, antigen presentation and effector 
functions are diminished222,223. Instead, the accumulation of Tregs has been reported224-
226. Despite this actively induced immunosuppression, gliomas still seem to be 
dependent on the CNS-specific immunologic peculiarities, as they rarely metastasize 
outside the brain227 and only in the brain – compared to s.c. growth – unfold their full 
immunosuppressive nature213. However, the immunosuppressive microenvironment 
can be reverted by blockage of these cytokines or receptors, at least in experimental 
settings228-232. Overcoming this suppressive microenvironment in the vicinity of the 
glioma leads to increased infiltration of inflammatory leukocytes and eventually to an 
anti-tumor immune response. 
1.4.5 IL-12 and IL-23 in glioma tumorimmunology 
There are no specific studies on the role of IL-12 during the elimination phase of 
glioma immunoediting using cytokine deficient animals. It is likely though that 
specific IL-12 deficiency would result in increased incidence of spontaneous or 
induced tumors or accelerated growth of transplantable tumors. Polymorphisms in 
3´untranslated region (UTR) of the human IL-12 gene that lead to decreased IL-12 
production, have been implicated in increased susceptibility to glioma233. The 
therapeutic application of IL-12 in various animal models is compelling for many 
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types of tumors including gliomas234-236. After the initial drawbacks with systemic 
application of IL-12 in various other cancers (see 1.3.1.1), research in recent years has 
mainly focused on various local administration routes of IL-12 for glioma 
therapy235,237-240. Open questions remain on the exact mechanisms by which IL-12 
exerts its tumor-suppressive properties. Earlier publications suggest that IL-12 
mediated glioma control is mediated through activation of T-cells and NK-cells. 
However, rather few studies provided extensive functional data by systematically 
depleting the effector cells in question236,241-243. In light of the recently discovered 
tissue dependent differences of IL-12 induced tumor rejection (NK-cells: lung, 
NKp46+ ILCs: skin; see 1.3.1.1) it is tempting to speculate on the effector cells in the 
brain. Compared to IL-12, there are only few studies on the role of IL-23 in glioma 
immunobiology. Those studies reported potent anti-tumor activity in a DC-
vaccination setting or with transfected bone marrow derived neural stem cells to 
locally deliver IL-23180,181. 
1.4.4 Glioma and immunotherapy 
Immunotherapy to combat GBM has employed nonspecific approaches such as 
adoptive transfer of autologous immune cells and administration of adjuvants as well 
as specific approaches such as monoclonal antibodies (see 1.4.2) and DC vaccination 
strategies. While only tested in an animal model of 7 day established gliomas so 
far244, the systemic application of CTLA-4 neutralizing antibodies is promising, 
considering its success in metastatic melanoma116. Another strategy is to use 
bispecific hybrid antibodies; these hybrids bind to TAAs with one binding site and to 
T- or NK-cells with the other binding site (e.g. CD3), thereby facilitating cytolytic 
actions by physically attaching the effector cells to their targets. A preliminary trial 
combining these hybrid antibodies with adoptive transfer of autologous, in vitro 
activated NK- and T-cells yielded encouraging results245. Technical challenges in 
reagent production limited the number of patients treated, though. Clinical studies on 
adoptive immunotherapy were largely disappointing (reviewed in 246). Transfer of 
autologous, lymphokine activated killer cells (NK-cells and T-cells stimulated with 
IL-2) showed less efficacy than antigen specific ex vivo expanded CTLs derived from 
resected tissue, peripheral blood or lymph nodes. These cells were transferred directly 
into the resection cave after debulking or injected i.v. Even though some studies 
reported an increase in median survival, the use of active immunotherapy is regarded 
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as the most promising approach to date. Inactivated autologous tumor cells as 
vaccines (s.c. injection) combined with adjuvants (such as GM-CSF247 or genetically 
modified IL-4 secreting fibroblasts248), seems to be inferior to DC vaccination 
approaches. Being the most widely studied modality, this method has progressed to 
phase II clinical trials. In a study reported by Wheeler and colleagues, autologous 
DCs derived from peripheral blood mononuclear cells and pulsed with tumor cell 
lysates were injected s.c. into patients with recurrent or newly diagnosed GBM249. 
This resulted in an increase in overall survival of over 3 months. Other methods 
include fusion of DCs and tumor cells250, pulsing of DCs with acid eluted tumor 
antigens251 or tumor RNA252. DC vaccination has also been combined with systemic 
IL-12 application253. In most studies, active and passive cellular therapy approaches 
induced systemic immunity against TAAs, however this did not necessarily translate 
into clinical responses. It is likely that the local immunosuppressive environment 
prevents tumor clearance in presence of systemic immunity against the malignancy. 
Even though a recent trial testing an inhibitor of TGF-β to reduce immunosuppression 
in gliomas was announced as a success by the authors254, this interpretation is 
questionable255,256. Despite promising preliminary results, immunotherapy still has to 
overcome the often encountered low efficacy to become part of standard treatment 
protocols for GBM.  
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1.5 Aims of the study 
Initially the goal of this study was to systematically analyse the role of IL-12 and IL-
23 in a murine model of GBM. While for the former a tumor-suppressive role is 
rather well established in the literature, the latter has not been investigated in the 
glioma-context in great detail so far. Since the effector cells of an IL-12 mediated 
immune response seem to vary between tissues, the exact composition and 
contribution of different immune cells and their mechanism of action in glioma 
rejection is of utmost interest. This would allow the design of combinatorial treatment 
approaches that could boost IL-12 treatment regimens, taking into consideration the 
special immunologic situation in the CNS. On the basis of previous studies in glioma 
models, IL-23 holds the promise of being another candidate for immunotherapy 
against GBM. However, recent publications rather add IL-23 to the group of tumor-
promoting cytokines. To clarify this issue, IL-12 and IL-23 were locally expressed in 
Gl261 cells. The effects of local expression on the intracranial growth of Gl261 cells 
in C57Bl/6 and various molecularly well-defined immunodeficient animals were 
investigated. On the basis of the results from the above studies, successful 
immunotherapeutic approaches to treat established experimental gliomas have been 
developed.  
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2 Results 
2.1	  The	  effects	  of	  IL-­‐12	  and	  IL-­‐23	  expression	  in	  Gl261	  cells	  
To determine whether or not IL-12 and IL-23 are suitable candidates to overcome the 
local immunosuppressive environment induced by gliomas and to shed light on the 
effector mechanisms involved, we expressed either of these two cytokines in Gl261 
mouse glioma cells212.  
2.1.1	  Gl261-­‐luc,	  a	  cell	  line	  suitable	  for	  bioluminescent	  in	  vivo	  imaging	  
Experimental s.c. tumors are readily accessible for the assessment of their volume via 
size measurements using a caliper. Lung metastasis models usually do not measure 
tumor development over time, but use fixed end-point analyses such as colony 
counting148. Intracranial tumor-growth can also be monitored by fixed end-point 
analyses via histological sampling, however to follow the tumor-growth and/or 
rejection over time in a non-invasive manner, imaging-methods such as small animal 
magnetic resonance imaging (MRI) are necessary257. An alternative to this expensive 
and time-consuming method is the use of bioluminescent imaging (BLI). Though not 
as accurate in spatial resolution, it represents a less costly and easy-to-handle 
alternative to MRI. Upon systemic injection of the substrate luciferin, light emitted by 
luciferase-positive genetically modified tumor cells is detected via a highly sensitive 
CCD-camera system. To this end, we stably transfected Gl261 cells with photinus 
pyralis luciferase, constitutively driven by an SV40 promotor. We termed these cells 
Gl261-luc (To keep the identifier of cells transfected with cytokine constructs short, 
the addition “-luc” will however be omitted in the following text). 
2.1.2	  Expression	  of	  IL-­‐12	  and	  IL-­‐23	  single	  chain	  Fc-­‐fusion	  constructs	  
IL-12 and IL-23 are heterodimers consisting of a common p40 subunit and distinct 
p35 and p19 subunits, respectively. Once the two subunits are bound to each other via 
disulfide bonds, the mature cytokine is secreted as a dimer. For increased stability and 
solubility, we used single chain fusion constructs with an Fc-tag to express IL-12 and 
IL-23148,168,258. Unlike the endogenous cytokines, the two subunits are fused together 
only separated by a flexible linker peptide and are translated together as a single 
protein. Moreover, at the c-terminal end the constant part (the c-terminal 6 amino 
acids of CH1 up to CH3) of the murine Immunoglobulin-G3 (IgG3) heavy chain is 
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fused in-frame to the cytokine subunits. As a control construct, we used the IgG3 
heavy chain fragment without the cytokine subunits (Fig 6A). Constitutive eukaryotic 
expression was ensured using the CMV-promotor of a commercially available vector 
backbone (pCEP4, Invitrogen®). After stable transfection of Gl261-luc cells we 
confirmed secretion of IL-12 and IL-23 by enzyme-linked immunosorbent assay 
(ELISA) for their common subunit IL-12/23 p40 and for the specific IL-12 p70 and 
IL-23 p19 subunits (Fig 6B and data not shown). We further confirmed expression of 
the Fc tail by reverse transcriptase (RT)-PCR (Fig 6C). The cytokine secreting, 
luciferase positive cell lines were termed ‘Gl261 IL-12’, ‘Gl261 IL-23’ and ‘Gl261 
Fc’. The transfection with the episomal expression vector coding for cytokine 
constructs did not seem to interfere with the expression of luciferase as the cells still 
exhibited comparable levels of photon emission in vitro (Fig 6D).  
 	  
Figure 6: Expression of luciferase and IL-12 or IL-23 in Gl261 cells A) IL-12 and IL-23 are 
heterodimers, left: subunits of the respective cytokines, connected via disulphide bonds 
(dotted lines), right: schematic representation of IL-12, IL-23 single chain fusion constructs 
with a mouse IgG3 Fc-tag and the Fc-only control construct B) IL-12/23 p40 detected in the 
supernatant of transfected Gl261 cells via ELISA, 5000 cells/well 4d culture C) RT-PCR 
specific for the murine IgG3 tag, a vector DNA coding for the IgG3 tag was used as positive 
control (pCEP4 Fc) D) luminescence emitted by 50´000 cells per well, plated in a 48 well 
plate, triplicates shown. Data representative of at least three independent experiments. 
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2.1.3	  Characterization	  of	  IL-­‐12	  and	  IL-­‐23	  expressing	  glioma	  cells	  
During the process of stable transfection, random integration of DNA (i.e. the above 
mentioned luciferase sequence) into the genome of a cell can lead to phenotypic 
changes. In addition, the expressed cytokines may have an unanticipated effect on 
their own on the tumor cells. To assess possible autocrine effects of the cytokine 
expression on Gl261 cells themselves we compared the proliferation of the transfected 
cells with the parental cells and found them not to be significantly different (Fig 7A). 
We next compared the ability to form brain tumors in wt mice. In an initial 
experiment we tested whether the expression of luciferase and the subsequent 
transfection of cytokine expression vectors already led to a significant reduction of 
tumor penetrance and progression. Gl261 and Gl261 Fc would both readily form 
tumors, Gl261 Fc-bearing animals showing a slightly increased median survival time 
(Fig 7B). Compared to Gl261 Fc cells, Gl261 IL-12 cells show a clear reduction of 
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Figure 7: Analysis of IL-12 and IL-23 expressing Gl261 cells A) 3H-Thymidine 
incorporation of 5´000 cells/well over 4 days; Data representative of at least three 
independent experiments B) 2x104 Gl261-luc cells were injected into the right striatum, Upper 
graph: Quantification of bioluminescence emitted from wt animals injected with parental 
Gl261 (open diamonds, n=5) or luciferase expressing Gl261 Fc (open triangles, n=4) cells. 
Photon flux is plotted on a logarithmic scale. Lower graph: Kaplan Meier survival C) 
Quantification of ROI photon flux of Gl261 Fc-tumor bearing wt (open triangles) or IL-12rβ2-/- 
(filled triangles) animals, and Gl261 IL-12-tumour bearing wt (open circle) or IL-12rβ2-/- (filled 
circles) animals; n=6/group Error bars denote standard deviation D) Correlation of tumor 
volume versus bioluminescence (BLI), trendline: linear fit, 95% confidence interval shown, 
Samples derived from tumor bearing animals sacrificed at d35 and d21 after inoculation (IL-
12, IL-23, Fc; Fig. 8A and data not shown).  
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emitted photons when injected in wt animals. This effect is gone when animals 
deficient for the IL-12 specific subunit of the IL-12R, Il-12rβ2-/- mice, are used as 
hosts. Gl261 Fc cells, on the other hand, grow equally well in wt and Il-12rβ2-/- hosts 
(Fig 7C). Taken together, these findings imply that IL-12 and IL-23, expressed by 
Gl261 cells, act on cells of the host rather than on the tumor themselves. To test the 
reliability of BLI-monitoring to follow the intracranial tumor growth, we compared 
the amount of emitted light with the tumor size derived by serial histological 
sampling. Luminescence readings and tumor volume as assessed by stereologic 
methods showed a robust correlation (7D). 
2.1.4	   Intratumoral	   expression	   of	   IL-­‐12	   but	   not	   IL-­‐23	   leads	   to	   rejection	   of	  
experimental	  gliomas	  
To investigate the effects of cytokine secretion on intracranial tumor growth, we next 
implanted Gl261 IL-12, IL-23 and Fc into the right striatum of syngeneic C57Bl/6 
mice and followed tumor growth via BLI monitoring. After an initial increase in 
luminescence all groups showed a depression around day 14 post injection. Animals 
bearing IL-23 and Fc expressing tumors exhibited a steep increase in BLI and soon 
reached withdrawal criteria, sometimes even before day 35 post injection. In contrast, 
BLI-readings for animals that had been injected with IL-12 expressing Gl261 tumors 
dropped to levels close to the detection limit at day 21 onwards (Fig 8A). To verify 
this finding we also performed histological analyses. In agreement with the above 
observations we could only detect a residual tumor in some animals in the Gl261 IL-
12 group, while Gl261 IL-23 and Gl261 Fc injected animals showed robust tumor 
formation (Fig 8B). The reduction of tumor size in mice injected with Gl261 IL-12 
tumors and the increased tumor size in animals injected with Gl261 IL-23 tumors 
suggested contrasting roles of these two cytokines in tumor-rejection. To test whether 
this phenomenon would persist over a prolonged period of time and whether it would 
translate into a clinical difference in the progression of the glioma, we performed 
survival studies. When we followed animals that had been implanted with Gl261 IL-
12 or Gl261 Fc cells for up to 90 days, we observed rejection of the tumor in a high 
proportion of mice bearing IL-12 secreting tumors after an initial establishment (Fig 
8C). While IL-12 expression conferred a significant survival advantage, IL-23 
secretion appeared to be tumor promoting. Gl261 IL-23 tumor bearing animals 
succumbed to the tumor even faster than controls (Fig 8D). As the observed 
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differences are hardly attributable to an autocrine effect of the expressed cytokines on 
the glioma cells themselves (Fig 7A-D), it is likely that the observed differences are 
due to effects on host cells, most likely from the immune compartment. Therefore, we 
next analyzed the infiltration of the tumor bearing hemispheres by myeloid cells and 
lymphocytes.  
 	  
Figure 8: Intratumoral expression of IL-12 but not IL-23 leads to rejection of 
experimental gliomas 2x104 Gl261 cells were injected into the right striatum A) Weekly BLI-
monitoring of tumor bearing wt animals (Gl261 Fc: open triangles, Gl261 IL-12: open circles, 
Gl261 IL-23: open boxes, n=6/group). Quantification of total ROI photon flux, note that one 
Gl261 IL-23 bearing animal reached withdrawal criteria before day 35 post inoculation. 
Photon flux is plotted on a logarithmic scale B) Histologic samples of experiment in A), 
timepoint d35. F4/80 positive cells are stained in brown, cell nuclei in blue. Largest tumor 
cross-sections shown; arrow head: remaining tumor C) Upper graph: Quantification of 
bioluminescence emitted from wt animals injected with Gl261 Fc or Gl261 IL-12 cells and 
followed for 90 days. Lower graph: Kaplan Meier survival plot for the same experiment; 
pooled data from two independent experiments; 12 animals per group D) Upper graph: 
Quantification of bioluminescence for wt animals injected with Gl261 Fc (n=10) or Gl261 IL-23 
(n=11) cells and followed for 90 days. Lower graph: Survival analysis for the animals 
described above; pooled data from two independent experiments. Error bars denote standard 
deviation. Scalebar in B): 2 mm 
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2.1.5	  Cytokine	  dependent	  infiltration	  of	  experimental	  gliomas	  
Since the observed differences in luminescence were already apparent at 21 days after 
tumor inoculation, we assumed that the expressed cytokines had an effect on the 
host´s immune cells already earlier than that time-point. Therefore we sectioned 
brains derived from tumor bearing animals at day 14. At this time-point it is likely 
that differences in the influx of host derived cells into the tumors become apparent. 
Indeed, we observed an increase especially in CD4 positive T-cells in IL-12 and IL-
23 expressing tumors with a slightly higher amount of CD4+ T-cells found in Gl261 
IL-12 gliomas. The number of CD8 positive T-cells increased as well, predominantly 
in IL-12 expressing tumors. T-cells were situated within the bulk tumor and especially 
at the tumor margins. In addition to CD4 and CD8 positive T-cells, we also observed 
higher numbers of macrophages/microglia as assessed by CD11b immunoreactivity 
(Fig 9). Differences in the distribution and number of asialo GM1 and CD11b positive 
cells were less apparent between groups. CD11b positive macrophages/microglia 
were slightly more dispersed within the tumor mass in Gl261 IL-12 tumors and 
surprisingly NK-cells in IL-12 expressing tumors appeared to be slightly reduced 
Figure 9: Tumor infiltrating leukocytes in cytokine expressing tumors 2x104 Gl261 cells 
were injected into the right striatum. Tumor infiltrating leukocytes were analysed by histology 
at day 14 after tumor inoculation. Brains of tumor-bearing animals were sectioned and stained 
for T-cells (CD4 and CD8), NK-cells (NK-asialo GM1) and macrophages/microglia (CD11b). 
Tumor margin is delineated by dotted line (upper part of pictures brain parenchyma, lower 
part of pictures tumor tissue); pictures representative of at least 3 animals/group; scale bar 
200µm.  
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compared to IL-23 expressing tumors. It is well established that gliomas induce a 
highly immunosuppressive microenvironment (see 1.4.4), one characteristic being the 
accumulation of Tregs. Since our initial aim was to convert this immunosuppressive 
environment into a pro-inflammatory one that facilitates tumor elimination, we tested 
for the frequency of Tregs in Gl261 Fc, Gl261 IL-12 and Gl261 IL-23 expressing 
tumors. Moreover, it is well known that IL-12 induces and maintains TH1 immune 
responses (1.3.1). IL-23, on the other hand, is implicated in TH17 responses (1.3.2). 
Thus, we set out to test for the expression of characteristic markers for these T-cell 
subtypes on CD4 positive T-cells by flow cytometry. We isolated invading leukocytes 
from tumor bearing animals and stained for FoxP3, IFN-γ and IL-17 to get an 
estimate for the presence of Treg, TH1 and TH17 cells, respectively. To look at a time-
point when differences can be apparent in BLI and to increase the availability of 
tumor tissue, we now isolated tumors at 21 days post injection. Indeed, in first pilot 
experiments using pooled samples, we observed a reduction of FoxP3 positive CD4 
T-cells in IL-12 expressing tumors (Fig 10A). There was also a slight tendency 
towards an increased IFN-γ production. Concerning IL-17, we detected only few 
positive cells, most of them where found in IL-23 expressing tumors. Repeating this 
analysis with single animals the initial tendencies proved to be reproducible and 
significant. The frequency of FoxP3+/CD4+ Tregs was reduced roughly by half, while 
the IFN-γ expressing CD4+ T-cells increased in IL-12 vs control tumors (Fig 10B). 
However, compared to Gl261 Fc tumors, Gl261 IL-23 gliomas did only show a slight 
reduction in FoxP3 positive cells and no change in the frequency of IFN-γ expressing 
CD4+ T-cells. We did not detect any difference in the IL-17 expression among the 
three experimental groups. Of note, the analysis of single animals might not yield 
enough cells for a robust and reproducible intracellular cytokine staining for IL-17. 
Cells expressing IL-17 were already scarce in pooled samples. Taken together, our 
results indicate that the expression of IL-12 within Gl261 cells leads to an influx of 
CD4+ and CD8+ T-cells as well as NK-cells and to a reduction of FoxP3+/CD4+ cells 
as well as an increase in IFN-γ expression by TH cells. While IL-23 does not seem to 
result in a successful reversal of the immunosuppressive environment, we found 
indications that IL-12 expression indeed leads to a reversal to a more inflammatory 
phenotype of infiltrating T-cells. 
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Figure 10: CD4+ Tumor infiltrating lymphocytes in cytokine expressing tumors 2x104 
Gl261 cells were injected into the right striatum. A) Flow cytometric analysis of invading CD4 
positive T-cells at day 21 post tumor inoculation. Rostral part of tumor bearing hemispheres 
were homogenized and invading leukocytes isolated and stained. Dot plots show CD4 
positive cells after duplet exclusion and gated on live CD45 hi and CD11b/NK1.1 neg cells. 
Pooled data from 4 animals/group. B) Scatter plots on the right depict indicated gate 
frequencies of single animals after exclusion of dead cells and duplets; gated on CD45 hi, 
CD11b neg and CD4 positive cells. Pooled data of two independent experiments with 5-6 
animals/group; significance level: p<0.05; ANOVA, followed by Tuckey´s post test 
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2.2	  Mechanisms	  of	  IL-­‐12	  mediated	  rejection	  of	  experimental	  glioma	  
So far, our results suggested that both IL-12 and IL-23 lead to an influx of immune 
cells to the tumor and its direct vicinity, but only IL-12 mediates a tumor-suppressive 
immune response. IL-23 secretion rather seems to lead to an inefficient hyper-
inflammatory status that does not result in an anti-tumor effect. Therefore we next 
focused on the effector mechanisms of IL-12 mediated glioma rejection. 
2.2.1	  T-­‐cells	  rather	  than	  NK-­‐cells	  are	  crucial	  for	  IL-­‐12	  mediated	  glioma	  rejection	  
T and NK cells are among the most prominent IL-12 responsive leukocytes and to 
systematically test the functional relevance of the IL-12 mediated influx of these cells, 
we challenged a series of mouse mutants with intracranial Gl261 IL-12. We implanted 
Gl261 IL-12 cells in mice that lack T and B cells (Rag1-/-)60 or conventional NK-cells 
(Il-15ra-/-)47 or in mice lacking both T-, B-, NK-cells and also the lymphoid tissue 
inducer like cells, among other cell types (Rag2-/- Il2rg-/-)149 (Fig 11A). The absence 
of the distinct effector cell population in respective mouse mutants should lead to 
Gl261 IL-12 tumor growth similar to that of Gl261 Fc tumors in wt animals. After an 
initial lag phase until day 14 after injection all groups exhibited a strong increase in 
luminescence until day 28. Between days 28 and 42 most of the animals succumbed 
to the tumors. Only wt and Il-15ra-/- mice were able to control the tumor and showed 
a significantly prolonged survival compared to Rag2-/- Il2rg-/- and Rag1-/- animals. 
While T or B-cells appeared to be crucial for IL-12 mediated glioma rejection, the 
ability of Il-15ra-/- mice to reject Gl261 IL-12 indicates that NK cells were largely 
expendable. Moreover, since the survival curves of Rag2-/- Il2rg-/- and Rag1-/- animals 
are almost indistinguishable, it is highly unlikely that another cell type is playing an 
essential role similar to T-cells.  
2.2.1.1	  CD8+	  together	  with	  CD4+	  T-­‐cells	  mediate	  IL-­‐12	  induced	  glioma	  control	  
We next investigated the contribution of CD4 and CD8 positive T-cells using MHC 
class-II (Ia(b)-/-)259 and MHC class-I (β2m-/-)260 deficient mice.  In contrast to wt mice, 
Ia(b)-/- mice lacking CD4 T cells could not control Gl261 IL-12 tumors and β2m-/- 
mice succumbed to the glioma shortly after (Fig 11B). These data demonstrate that 
IL-12 mediated tumor rejection is dependent on the activity of T cells including 
helper T cells and CTLs. The clear difference between CD4 T-cell deficient and CTL 
Results  Effector Mechanisms 
 
 62 
deficient animals also suggests the need for TH derived instruction and support for the 
maximal tumoricidal activity of CD8 positive cytotoxic T-cells. Since we did not 
observe B-cells in neither Gl261 Fc nor Gl261 Il-12 tumors via histology or FACS 
Figure 11: Effector cells of IL-12 mediated tumor rejection 2x104 Gl261 IL-12 cells were 
injected into the right striatum A) Upper graph: quantification of ROI photon flux of tumor 
bearing wt (open circles, n=14), Rag1-/- (filled light grey circles, n=12), Rag2-/- Il2rg-/- (filled 
dark grey circles, n=11) and Il-15ra-/- (filled black circles, n=10) animals. Lower graph: Kaplan-
Meier survival analysis; Pooled data from two independent experiments; 10-14 animals per 
group B) Upper graph: quantification of ROI photon flux of tumor bearing wt (open circles, 
n=16), β2m-/- (filled light grey circles, n=12) and Ia(b)-/- (filled black circles, n=16) animals. 
Lower graph: Kaplan-Meier survival analysis; Pooled data from two independent experiments 
C) 90 days after injection of 2x104 Gl261 IL-12 cells into the right striatum, surviving wt 
animals (from experiments described in B) and Fig 11 A) were rechallenged with 2x104 Gl261 
Fc cells into the left striatum. Left panel: representative pictures of bioluminescence at days 1, 
7 and 14 after the 2nd injection for rechallenged animals. Note the presence of a 
bioluminescent signal at day one and its absence at day 7 in the survivor. Graph on the right 
shows quantification of ROI photon flux of rechallenged mice (7 survivors, 9 naïve wt). Pooled 
data from two independent experiments; Log-rank (Mantel-Cox) Test was used to calculate p-
values indicated in A) and B). Error bars denote standard deviation. 
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(data not shown) and since B-cell responses in MHCI deficient animals are unlikely to 
be impaired we further focused on T-cells as putative effector cells of IL-12 induced 
glioma rejection.  
2.2.1.2	  Memory	  formation	  in	  surviving	  Gl261	  IL-­‐12	  challenged	  animals	  
To further investigate the character of the T-cell dependent tumor control we tested 
for memory formation in the surviving wt animals that had been previously 
challenged with Gl261 IL-12 cells (Fig 11C). The BLI readings of these animals had 
returned to baseline levels for weeks suggesting clearance of the initial tumor. In 
contrast to the primary challenge with Gl261 IL-12, we now injected Gl261 Fc cells 
into the contralateral hemisphere of survivors or naïve wt animals. Injected in the 
contralateral hemisphere, these cells would encounter a pristine local 
microenvironment without any possible residual immune cells left from an earlier 
rejection. We observed a rapid clearance of the Gl261 Fc control tumors within days. 
While the measured luminescence at day 1 suggested identical seeding across the two 
groups, only the naïve mice exhibited a measurable signal at day 7 onwards, 
suggesting a rapid and efficient anti-glioma memory response now independent of 
ectopically expressed pro-inflammatory cytokines. 
2.2.2	  Effector	  molecules	  of	  IL-­‐12	  mediated	  glioma	  rejection	  
T-cells seem to be crucial for the IL-12 mediated rejection of Gl261 experimental 
gliomas, but what is the molecular armament necessary for a successful rejection of 
these Gl261 IL-12 tumors? What are the signalling molecules involved? To this end 
we employed mutant animals lacking distinct immune-related effector molecules. 
2.2.2.1	  IFN-­‐γ	  deficient	  animals	  reject	  Gl261	  IL-­‐12	  
It is well established that IL-12 polarizes naive T-cells to adopt a TH1-phenotype261. 
IFN-γ is one of the main cytokines induced by IL-12132. Therefore we challenged 
mice deficient in the TH1 hallmark cytokine IFN-γ with IL-12 expressing Gl261 cells 
(Fig 12A). To our surprise we observed a similar capacity for tumor rejection in Ifn-g-
/- animals as in wt animals, suggesting that the mechanism of rejection is not crucially 
dependent on this cytokine. 
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2.2.2.2	  Perforin,	  a	  cytolytic	  molecule	  crucial	  for	  IL-­‐12	  mediated	  glioma	  rejection	  
Conversely, IL-12 also stimulates the cytotoxic activity of CTLs. When we analyzed 
the role of Perforin, a cytolytic molecule primarily expressed on CD8+ CTLs and NK-
cells262, but also found on still enigmatic CD4+ CTLs263, we observed a clear 
difference in survival curves (Fig 12B). In contrast to Ifn-g-/-, Perforin-deficient 
animals (prf1-/-) were not able to control the tumor, when compared to wt animals. 
This further supports the notion that T-cells, CD4+ as well as CD8+, are the main 
effector cells of IL-12 mediated glioma rejection. 
 
 
Figure 12: Perforin is crucial for IL-12 mediated tumor rejection, Interferon-γ is 
expendable 2x104 Gl261 IL-12 cells were injected into the right striatum and tumor growth 
was followed for 90 days A) Upper graph: quantification of ROI photon flux of tumor bearing 
wt (open circles, n=12) and Ifn-g-/- (filled black circles, n=10) animals. Lower graph: Kaplan-
Meier survival analysis; Pooled data from two independent experiments B) Upper graph: 
quantification of ROI photon flux of tumor bearing wt (open circles, n=14) and Perforin-/- (filled 
black circles, n=13) animals. Lower graph: Kaplan-Meier survival analysis of the animals 
above; Pooled data from two independent experiments; Log-rank (Mantel-Cox) Test was 
used to calculate p-values indicated in A) and B). Error bars denote standard deviation. 
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2.3 Combination therapy approaches for advanced experimental glioma 
Thus far we had focused on elucidating the mechanisms of IL-12 mediated tumor 
rejection in a preventive manner by local expression within glioma cells. To translate 
our approach towards a more clinically relevant setting, we tested IL-12 application in 
mice with advanced stage tumors. Our results suggested that T-cells are a crucial cell 
type for IL-12 induced glioma rejection. However, the likelihood that a single 
treatment induces a tumor clearing immune response in advanced stages of disease is 
small. Accordingly we reasoned that a combination of IL-12 and an effector T-cell 
activating agent could boost the observed anti-tumor effect of IL-12. The blockade of 
the co-inhibitory molecule CTLA-4 does not only lead to increased TH- and CTL- 
efficiency but also inhibits the activity of Tregs, thus counteracting the 
immunosuppressive mechanisms induced by the tumor itself264.  
 2.3.1 Systemic application of recombinant IL-12 combined with CTLA-4 
blockade 
To test a combination treatment approach for advanced glioma consisting of IL-12 
application and CTLA-4 blockade, we applied systemic treatment to animals that had 
been challenged with Gl261 Fc 21 days before and that already exhibited strong BLI-
signals indicating an advanced stage of glioma growth (also compare Fig 15B). These 
animals were split in four groups and either received phosphate buffered saline (PBS, 
vehicle), αCTLA-4 mIgG2b, recombinant IL-12 or both via repeated i.p. injection 
(Fig 13). Following the tumor-bearing animals over time, a synergistic effect of 
combination treatment was apparent and led to a significant increase in survival. 
Conversely, at this late stage, single treatments did not lead to a high proportion of 
long-term survivors. Neither rIL-12 nor αCTLA-4 application did result in a 
significant increase in survival. Even though systemic levels of recombinant IL-12 
and αCTLA-4 were replenished 3 times per week resulting in IL-12p40 serum levels 
of up to 5ng/ml (data not shown), it is questionable whether concentrations in the bulk 
tumor mass in the CNS reached effective concentrations to overcome the local 
immunosuppressive environment. Apart from low efficacy, systemic IL-12 
application is of low clinical relevance as has been discussed earlier (1.3.1.2). 
Nevertheless, the preliminary finding that application of IL-12 together with CTLA-4 
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blockade act synergistically in prolonging survival of tumor bearing animals 
encouraged us to refine our treatment approach.  
 
2.3.3	  Local	  treatment 
We next aimed at combining local, i.t. application of IL-12Fc and systemic CTLA-4 
blockade, hoping that the local application of IL-12 would increase the observed 
synergistic effect. 
2.3.3.1	  Purification	  of	  IL-­‐12Fc	  
Repeated local administration into a brain tumor is experimentally challenging, 
troublesome and a heavy burden for experimental animals. The continuous local 
intracranial administration of therapeutic agents via osmotic minipumps is a widely 
used approach that is well tolerated over several months (265 and S.Prokop, personal 
communication). We therefore aimed at local delivery using osmotic minipumps 
loaded with IL-12. Since these pumps would remain in a skin pouch situated at the 
animals back, we reasoned that rIL-12 would most likely loose effectiveness due to 
degradation, when incubated over several weeks at body temperature. A single chain 
Fc fusion protein should be more stable over prolonged periods of time. Therefore we 
expressed IL-12Fc in mammalian cells and purified it. Comparable amounts of rIL-12 
and IL-12Fc were analyzed by Western Blot analysis and silver staining under non-
reducing and reducing conditions. As expected, rIL-12 runs at 70 kDa and forms a 45-
Figure 13: Systemic administration of 
IL-12 in combination with CTLA4 
blockade in a therapeutic setting 2x104 
Gl261-luc Fc cells were injected into wt 
mice. At day 21 (arrow), tumor bearing 
animals were treated initially with αCTLA-
4 mouse IgG2b (9D9) (filled light grey 
triangles, n=8), recombinant IL-12 (rIL-12) 
(filled dark grey triangles, n=9) or a 
combination of both (filled black triangles, 
n=9) injected intraperitoneal (i.p.). The 
control group received phospate buffered 
saline (PBS, open triangles, n=7). 
Treatment was sustained 3x/week until 
the end of the experiment. Pooled data 
from two independent experiments Upper 
graph: quantification of ROI photon flux of 
tumor bearing wt animals receiving the 
indicated treatment. Lower graph: 
Kaplan-Meier survival analysis. 
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50 kDa doublet under reducing conditions266 (Fig14 A), detected by antibodies 
specific for IL-12p40 (Fig14 B). Reduced IL-12Fc runs at approximately 100 kDa and 
forms a 200 kDa dimer under non reducing conditions.  
2.3.3.2	  Local	  treatment	  directed	  against	  advanced	  glioma	  
21 days after Gl261 Fc inoculation, osmotic minipumps delivering IL-12Fc or PBS 
directly into the tumor were implanted. At this timepoint, the tumor is of considerable 
size (illustrated here in two unrelated tumor samples with indicated photon flux) and 
emits an ROI flux between 1x105 – 1x108 p/s with and average flux of 2x107 p/s (Fig 
15B). Tumor bearing animals were split into four groups and either received PBS 
(vehicle), αCTLA-4 mIgG2b, purified IL-12Fc or both (Fig 15A). Starting one day 
after implantation of the minipumps, the animals received αCTLA-4 mIgG2b 
antibodies or PBS via i.p. injections as indicated. Monotherapies with intratumoral 
application of IL-12Fc or αCTLA-4 alone conferred only a minor or no significant 
survival advantage, respectively. Strikingly, local IL-12Fc administration into the 
tumor in combination with systemic CTLA-4 blockade led to a remission of BLI flux 
in over 80% of animals within two weeks. A similar albeit weaker trend was visible in 
the majority of IL-12Fc/PBS treated animals, but only resulted in survival of two out 
of seven animals until day 90. Three out of 11 animals receiving combination 
treatment exhibited increasing BLI readings after an initial reduction around 5 weeks 
after initiation of treatment, 2 of those reached withdrawal criteria until the end of the 
experiment, while one survived without clinical signs until 90 days after inoculation. 
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Figure 14: Purification of IL-12 single chain fusion protein IL-12Fc was purified from 
supernatant of transiently transfected cells, dialyzed and subjected to SDS-PAGE. A) 
Silverstaining and B) immunoblot of equal amounts of recombinant murine IL-12 (rIL-12) and 
IL-12Fc. Reducing and non-reducing conditions are indicated as presence or absence of 
dithiothreitol (DTT). Size standard indicates molecular weight in kDa. Note the absence of the 
IL-12Fc dimer in reducing conditions. 
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Except for this one mouse with increasing BLI readings from day 70 onwards, careful 
histologic assessment of the brain tissue of surviving animals around the initial 
injection site did not reveal any residual tumor tissue (Fig 15C). This is in agreement 
with the recorded ROI flux for the respective animals (∼104 p/s) and also applies to 
surviving animals receiving IL-12Fc monotherapy. Apart from scar tissue and 
considerable presence of F4/80 positive microglia/macrophages only few infiltrates 
remained at the original implantation site, while the contralateral hemisphere was free 
any signs of microglial activation. No signs of autoimmunity such as EAE 
symptoms(limp tail, hind leg weakness, weight loss) have been observed throughout 
the experiments.  
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Figure 15: Local administration of IL-12 in combination with systemic CTLA-4 blockade 
leads to rejection of advanced gliomas 2x104 Gl261 Fc cells were injected into the right 
striatum of wt mice and tumor growth was followed for 90 days. A) at day 21 (arrow), osmotic 
minipumps delivering 50ng IL-12Fc/day (or PBS) into the tumor were implanted into glioma 
bearing animals. 28 days later, empty pumps were explanted from surviving animals. Animals 
received i.p. injections with 200µg of αCTLA-4 or PBS at day 22, followed by injections of 
100µg αCTLA-4 or PBS on days 26, 29, 35 and 42 (PBS/PBS: open triangles, n=12; 
PBS/αCTLA-4: filled light grey triangles, n=9; IL-12Fc/PBS: filled dark grey triangles, n=7; IL-
12Fc/αCTLA-4: filled black triangles, n=11). Upper graph: quantification of ROI photon flux in 
tumor-bearing wt animals receiving the indicated treatment. Lower graph: Kaplan-Meier 
survival analysis; Pooled data from three independent experiments. B) Two independent, 
unrelated examples of Gl261 tumors at day 21, emitted ROI flux is indicated, Hematoxylin & 
Eosin (HE) staining C) HE staining and F4/80 immunoreactivity of a representative survivor, 
treated with IL-12Fc/αCTLA-4 as indicated in A), sacrificed at day 91. Upper panel overview; 
arrowheads indicate approximate former tumor center and area covered by high 
magnification pictures; scale bar 200µm  
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2.3.3.3	  Impact	  of	  combination	  treatment	  -­‐	  preliminary	  observations	  
To gain first insights into the events leading to the observed reduction of BLI readings 
and ultimately to rejection of established d21 gliomas, we sacrificed animals before 
therapy onset and two weeks after beginning of treatment and analyzed them via 
histology (Fig 16) and flow cytometry (Fig 17). 
2.3.3.3.1	  Histological	  analysis	  
Before initiation of treatment, we observed weak infiltration of CD8+ and NK-cells 
(asialo GM1+) resembling the situation at day 14 post injection in Gl261 Fc cells. 
CD11b immunoreactivity was also comparable to this earlier time point, but slightly 
more positive within the bulk tumor. CD4+ T-cells are well detectable within the bulk 
tumor mass and the surrounding brain parenchyma. As has been described before for 
the Gl261 model (1.4.3.2), the tumor appears clearly circumscribed with rather 
smooth margins. This overall appearance does not substantially change in a control 
animal (PBS/PBS), two weeks after treatment, except for a weak increase in CD8+ 
cells. The same holds true for an animal that received αCTLA-4 monotherapy 
(PBS/αCTLA-4). However, when we analysed an animal receiving IL-12Fc 
monotherapy (IL-12Fc/PBS), the staining for all four markers intensified considerably 
suggesting an increased infiltration of immune cells into the tumor tissue. Not only T-
cells, but also NK-cells seemed to respond to IL-12 treatment. The tumor margins 
seemed less clearly distinct compared to the above samples. Moreover, tissue damage 
within the tumor started to become apparent in some sections. The extent of tissue 
damage was more pronounced and actually the most striking characteristic in sections 
derived from a mouse receiving combination treatment (IL-12Fc/αCTLA-4). It is 
tempting to speculate that this is the histological correlate to the reduced BLI readings 
around d35. Close to these areas CD11b positive cells were situated. To our surprise 
we only discovered few CD4+ T-cells within the tumor and at the tumor margin. NK 
cells seemed to increase in number, especially within the tumor. Concerning the 
presence of lymphocytes at the periphery and within the glioma tissue, CD8+ T-cells 
appeared to be the predominating population. These cells were well interspersed with 
the glioma cells and also accumulated in great numbers at the tumor margin. In 
summary, these first preliminary observations imply that local administration of IL-
12Fc into advanced stage gliomas achieves a reversal of the tumor-intrinsic 
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 immunosuppression, characterized by increased influx of effector cells. Moreover, 
there are first signs of on-going tissue destruction visible within the tumor, suggesting 
that this immune infiltration indeed leads to glioma rejection.  
 
 
  
Figure 16: Local administration of IL-12 in combination with CTLA-4 blockade leads to 
increase in effector cells and tissue damage within the bulk tumor Tumor infiltrating 
leukocytes were analysed by histology at day 21 after tumor inoculation (top row) and two 
weeks after treatment (d35 post injection). Brains of tumor-bearing animals were cryo-
embedded, sectioned and stained for T-cells (CD4 and CD8), NK-cells (asialo GM1) and 
macrophages/microglia (CD11b). Tumor margin is delineated by a dotted line (left: brain 
parenchyma, right: tumor tissue), arrowheads denote focal tissue destruction, a single animal 
per group from experiment depicted in Fig 15A) is shown; scale bar 200µm. 
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2.3.3.3.2	  Effects	  on	  tumor	  infiltrating	  T-­‐cells	  
To gain further insights into the consequences of combined treatment, we used the 
other halves of the tumors that had been analysed by histology, for flow cytometry. 
Staining for CD4 and CD8 positive T-cells revealed a partially similar ratio as implied 
by stained tissue sections (Fig 17A). Surprisingly, the proportion of CD8+ T-cells in 
control animals (PBS/PBS) and in animals treated with αCTLA-4 monotherapy 
(PBS/αCTLA-4) was higher than before treatment. Most strikingly, the number of 
CD4 positive T-cells increased considerably compared to IL-12Fc treated animals, 
while only very few CD8+ CTLs were found. In line with histological observations, 
we could hardly detect any CD4+ T-cells but a solid number of CTLs. Focusing again 
on the phenotype of TH cells as a readout for changes in the tumor microenvironment, 
we analysed the expression of FoxP3 to detect Tregs and IFN-γ as a marker for TH1 
polarized T-cells (Fig 17B). Comparing the situation before treatment and at d35 in 
PBS/PBS treated animals, the number of Tregs doubled, while the formerly robust 
expression of IFN-γ was greatly diminished. Even though αCTLA-4 treatment 
decreased FoxP3 expression, it had only a marginal effect on IFN-γ production. 
Under the influence of IL-12Fc, however, FoxP3 expression seemed to cease while 
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Figure 17: TILs after local administration of IL-12 in combination with CTLA-4 blockade 
2x104 Gl261 Fc cells were injected into the right striatum. Tumor infiltrating leukocytes were 
analysed by flow cytometry at day 21 after tumor inoculation (pooled sample of 3 individual 
animals) and two weeks after treatment (d35 post injection, single animals). Caudal parts of 
tumors were homogenized and TILs isolated and stained. Contour plots in A) show 
frequencies of CD4 and CD8 positive cells, gated on CD45high/CD11b negative, live cells 
after duplet exclusion, contour plots in B) show frequencies of CD4 positive cells as gated in 
A), expressing FoxP3 and IFN-γ. 
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only a minority of CD4+ T-cells did not produce IFN-γ, hinting at a powerful TH1 
response. Since CD4+ cells were extremely scarce in the animal receiving 
combination treatment, the few stained cells cannot be interpreted. In general, the 
analysis TILs by flow cytometry supports the observation that the combined treatment 
leads to a strong increase in CTLs and a decrease in TH cells. Since the tissue 
availability was very limited for this analysis, only few preliminary conclusions 
should be drawn. 
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3 Discussion 
3.1 Technical considerations 
3.1.1	  Experimental	  model	  
Orthotopic and syngeneic transplantable tumor models offer a reproducible and 
convenient way to model tumor growth in experimental animals. Tumors arising in 
mice treated with potent carcinogens, such as MCA in the case of Gl261 recapitulate 
various traits of their human counterparts212. Compared to cell lines derived from 
spontaneously arising tumors such as the spontaneous murine astrocytoma 
(SMA560267,268), Gl261 exerts less invasive and aggressive growth, though.  Both 
transplantable models do omit various stages of gradual malignant progression in 
terms of establishment and immunoselection compared to genetic models. Since the 
development of cancer rather follows stochastic patterns in these models, it is more 
challenging to develop protocols to study and treat animals of similar disease stages. 
Exploiting the reproducibility and the C57BL/6 background of Gl261, we investigated 
effector mechanisms of IL-12 induced glioma rejection and developed treatment 
strategies. We plan to validate our results in the SMA560 model before considering a 
confirmation in genetic models of GBM. 
3.1.2	  Bioluminescent	  imaging	  
BLI monitoring of solid tumors is a widely used means to follow tumor growth over 
time in a non-invasive fashion. Nonetheless, the light extinction of tissue has a 
significant impact on the sensitivity of this method. In C57BL/6 animals the dark fur 
color and variation of skin pigmentation over time in response to shaving and surgical 
implantation of the tumor cells leads to a loss of fidelity269. A change in skin 
pigmentation could explain the drop/stagnation of the luminescent signal observed at 
14 days post implantation. Moreover, edema formation and especially hemorrhages in 
late stage tumors mask light emitted from the bulk tumor. This could lead to the 
flattening of the BLI curve above an ROI flux of 1x107 - 1x108 p/s. Of note, the brain 
infusion cannula and the device holding it in place used for intratumoral infusion also 
shields light emitted by the tumor and also leads to a flattening of the BLI curve. In 
our study, BLI measurements should therefore be treated rather as a rough estimate of 
tumor progression than an unequivocal assessment of tumor size. 
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3.1.3	  Expression	  of	  luciferase	  in	  Gl261	  cells	  
Firefly luciferase expressed in a syngeneic tumor cell acts as a neoantigen and 
therefore can be considered as an artificial TAA. Even though luciferase positive cells 
can be passaged in vivo and readily form bulk tumors that eventually lead to the death 
of experimental animals, it is conceivable that an anti-tumor immune response might 
also target luciferase. Using parental SMA560 cells in a syngeneic background we 
will validate our treatment results in a luciferase negative glioma model.    
3.1.4	  Cytokine	  expression	  vectors	  
Episomal expression vectors such as the pCEP4® backbone used in this study stay in 
the cell as episomes and are replicated independently of the cell´s genomic DNA. 
This increases the copy number of sequences coding for the cytokine of interest and 
thus results in higher expression. In vitro, selection pressure by antibiotics (here: 
hygromycin) ensures high expression levels of the cytokine of interest. In vivo, this 
selection pressure is absent and despite the presence of genetic elements for episomal 
replication on the vector backbone, a loss of cytokine expression cannot be excluded. 
Loss of cytokine secretion could account for the variable numbers of long-term 
survivors challenged with Gl261 IL-12. We will analyze the presence of the cytokine 
in lysates of 21d established Gl261 Fc, Gl261 IL-12 and Gl261 IL-23 gliomas via 
immunoblotting for the common p40 subunit. 
3.1.5	  Quantitative	  flow	  cytometric	  analysis	  of	  tumor	  invading	  lymphocytes	  
FACS analysis of TILs requires on the one hand an amount of cells that 14 day 
established tumors do not yield yet. Even at day 21, there is a disparity in the 
frequency of CD4+/FoxP3+ between stainings on pooled samples and single animals, 
suggesting a threshold phenomenon for certain markers. On the other hand 
differences in size apparent at day 21 – when the tumor comprises more cells - 
hamper the analysis of absolute numbers of infiltrating cells. A known TAA 
expressed on Gl261 would facilitate the quantitative analysis normalized to the tumor 
size, as BLI is not sensitive enough for this purpose. Therefore we restricted our 
analyses here on the frequency of parental gates. Recently, the expression of bone 
marrow stromal antigen 2 (BST-2, also known as PDCA-1) has been reported on 
Gl261 in vitro and in vivo270. We could confirm this observation and will incorporate 
this marker into future analyses. 
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3.2 Mice bearing Gl261 IL-23 show reduced survival compared to controls  
Expressing IL-23 in Gl261 cells, we could not detect a significant autocrine effect on 
proliferation or surface expression of MHC class-I or -II molecules in vitro. Mice 
bearing Gl261 IL-23 tumors nevertheless showed significantly reduced survival 
compared to controls. This finding contradicts reports that expressed IL-23 locally in 
DCs or bone marrow derived neural progenitor cells to deliver it at the glioma 
site180,181. One possible explanation could be the expression of IL-23 by the tumor 
cells themselves versus the expression of IL-23 in non-tumor cells that are attracted to 
or injected into the tumor: While constitutive expression within the tumor rather leads 
to a tumor-fostering non-clearing inflammation, IL-23 delivery after tumor 
establishment may have distinctive effects. Even though differing from the previously 
mentioned studies in glioma, our observations are in line with a more recent study 
reporting a tumor promoting effect of IL-23. In IL-23 deficienct tumor bearing 
animals, local expression of IL-17 and CD31, a marker for blood vessels, decreased 
while CD8+ T-cells increase107. IL-17 is a strong inducer of angiogenesis, leading to 
enhanced tumor growth271. It is conceivable that IL-23 induces increased vessel 
density in Gl261 tumors; this has not yet been assessed in our model, though. Using 
flow cytometry on pooled samples, we have observed a distinct CD4+ IL-17+ cell 
population in IL-23 expressing tumors. Subsequent analysis of cells derived from 
single animals was hampered by low cell numbers. A recent study described the 
presence of TH17 cells in human glioma and Gl261 mouse glioma without functional 
characterization272. Interestingly, the authors report co-expression of FoxP3 and IL-17 
in a substantial amount of CD4+ T-cells. We observed neither a considerable number 
of IL-17+ nor FoxP3+/IL-17+ TH-cells in control tumors. It is also possible that IL-23 
exerts its tumor promoting effect entirely independent of IL-17182. We did however 
observe considerable FoxP3 expression in Gl261 IL-23 and Gl261 Fc in CD4+ T-cells. 
Local IL-23 expression attracted various immune cells of the innate and adaptive 
immune system. However, in our hands, it fails to revert the immunosuppressive 
tumor microenvironment and rather seems to lead to an inefficient tumor fostering 
inflammatory state. To our knowledge this is the first description of a tumor 
promoting effect of IL-23 in an experimental glioma model. Since we originally set 
out to investigate anti-tumor effects of IL-12 and IL-23 for potential clinical use, we 
focused our attention on the effector mechanisms of IL-12. 
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3.3 Effector mechanisms of IL-12 mediated glioma rejection 
3.3.1	  T-­‐cells	  are	  the	  major	  effector	  population	  in	  IL-­‐12	  induced	  glioma	  rejection	  
Using a syngeneic model and various immune-deficient mice, our data show that IL-
12 induced glioma rejection is critically dependent on CD4+ and CD8+ T-cells and 
leads to immunological memory. Several studies investigated the mechanisms of IL-
12 in glioma control, most of these in a DC-vaccination setting, in which IL-12 was 
used as an adjuvant241,242,273. Based mainly on antibody mediated depletion, a crucial 
involvement of NK-cells and T-cells (CD4+ and/or CD8+) in the IL-12 mediated 
rejection of experimental gliomas was reported. These reports are partially 
contradicting regarding the contribution of NK-cells compared to studies where no 
DC-vaccination regime was applied but IL-12 was produced in situ and genetic 
mutants were used236. Some of these studies have investigated tumors derived from 
subcutaneous (s.c.) injection of glioma cell lines273. However, we have previously 
shown that in a s.c. melanoma model a population NKp46+ ILCs is crucial for IL-12 
mediated tumor control. Moreover, s.c. growth of Gl261 IL-12 cells is even delayed 
in the absence of T-cells148. In light of other publications49,146,149 and our own 
observations148 on the effector cells of IL-12 mediated tumor suppression in various 
organs we set out to investigate the brain as a target tissue. Contrasting to the above 
mentioned organs, in the CNS, T-cells seem to be the major effector population while 
NK-cells play a minor role, since IL-15Rα deficient animals lacking conventional 
NK-cells47 retain the ability to reject IL-12 expressing Gl261 tumors. NKp46+ ILCs 
appear to be expendable as well as the survival curves of Rag1-/- and Rag2-/- Il2rg-/- 
animals challenged with Gl261 IL-12 are identical. Comparing MHC class-I (β2m-/-) 
and MHC class-II (Ia(b)-/-) deficient animals, we further narrowed down the effector 
T-cells. On the one hand, most NKT-cells require β2m, but are MHCII independent in 
their development274. On the other hand, γδ T-cells are found in normal numbers in 
β2m-/- animals260. Both MHCI and MHCII deficient animals succumb to the Gl261 
IL-12 glioma. Therefore it is unlikely that either of the above cell types plays a crucial 
role in IL-12 mediated glioma control. Even though they are present in MHCII 
deficient animals, CD8+ CTLs alone were not able to control the tumor in the absence 
of CD4+ cells. Conversely, a lack of CTLs in MHCI deficient animals also leads to a 
loss of IL-12 induced tumor control. Our data support the notion that mounting an 
anti-tumor CTL response is largely dependent on CD4+ T cell help68. Even though an 
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important asset of NK-cells262, perforin deficient animals probably lose the ability to 
reject Gl261 IL-12 because the cytotoxic potential of CTLs is reduced. Furthermore, 
our data do not exclude the possibility that CD4+ T-cells act as cytotoxic effector 
cells. In an adoptive transfer therapy model to cure established melanoma, they have 
been reported to kill in a perforin/granzyme but also MHC class-II dependent 
manner70. In agreement with earlier studies235,275, we observed memory formation, 
underlining the importance of T-cells as effector cells of IL-12 induced glioma 
rejection. 
3.3.2	  IL-­‐12	  induced	  glioma	  rejection	  in	  absence	  of	  IFN-­‐γ	  	  
The major downstream mediator of IL-12, the TH1 hallmark cytokine IFN-γ, seems to 
be less crucial than anticipated for successful glioma control. IL-12 succeeds in 
driving TH1 differentiation in absence of IFN-γ, its efficiency to do so is however 
slightly reduced276. IFN-γ deficient animals reject Gl261 IL-12 tumors at a similar 
rate as wt control animals. This finding is in contrast to studies on IL-12 induced 
rejection in a DC-vaccination setting using antibody mediated neutralization of IFN-
γ241,242, but agrees with a more recent report employing a 
transgenic mouse model to locally express IL-12236. IFN-γ is 
not the only cytokine that is secreted upon IL-12 signaling in 
target cells, though. Also GM-CSF and TNF-α secretion is 
induced in T-cells and NK-cells261. We cannot exclude that 
these can compensate for a loss of IFN-γ. Actually, we 
observed a robust upregulation of TNF-α in infiltrating CD4+ 
T-cells in Gl261 IL-12 compared to Fc or IL-23 expressing 
cells in a preliminary FACS analysis (Fig 18). Hence, it is 
likely that loss of IFN-γ can be compensated by other 
proinflammatory mediators induced by IL-12. 
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Figure 18: CD4+ Tumor infiltrating lymphocytes express 
increased levels of TNF-α in Gl261 IL-12 tumors 2x104 Gl261 
cells were injected into the right striatum. Flow cytometric analysis 
of invading CD4 positive T-cells at day 21 post tumor inoculation. 
Dot plots show CD4 positive cells after duplet exclusion and gated 
on live CD45 hi and CD11b/NK1.1 neg cells. Pooled data from 4 
animals/group. 
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3.3	  Treatment	  of	  advanced	  stage	  experimental	  glioma	  
Preventive and early treatment of tumors in preclinical models undoubtly allows the 
study of immunological mechanisms and the interactions between tumor cells and 
tumor microenvironment and thus contributes to the understanding of the disease and 
to the development of new therapeutic approaches. However, preventive therapy is of 
limited relevance for swift clinical translation of new treatment strategies. In the 
literature most therapeutic treatment regimens start at 5-7 days post injection of 
Gl261277. In rare cases, Gl261 studies - reporting a similar median survival of 
untreated controls as in our hands -have postponed the beginning of treatment to two 
weeks post injection278. With the beginning of treatment at 3 weeks post injection, we 
decided to choose an exceptionally late timepoint for intervention in a progressing 
and aggressive disease model. To closely mimic a clinical situation we allowed the 
tumor to progress to a size that is highly likely to cause significant neurological 
symptoms in humans. Here, therapy with i.t. IL-12Fc had a minimal albeit significant 
survival effect in our hands, while single therapy with systemic rIl-12 already failed. 
The same holds true for CTLA-4 blockade as monotherapy, which has been shown to 
be highly efficient against 7d established experimental SMA560 gliomas244. 
3.3.1	   Efficient	   tumor	   rejection	   after	   local	   IL-­‐12	   treatment	   in	   combination	   with	  
systemic	  CTLA-­‐4	  blockade	  	  
We already observed a weak synergistic effect when we combined systemic 
application of rIL-12 with systemic CTLA-4 blockade. Compared to the mild trend 
observed in this setting, the strong anti-glioma effect of local IL-12Fc infusion 
together with systemic CTLA-4 blockade is striking. Not only the frequency of 
responders to treatment assessed by BLI, but also the rate of survivors until day 90 
was impressive. Having the inevitable recurrence of human GBM after initial 
treatment success in mind, we cautiously looked for signs of remaining tumors in 
these survivors and but did not find any. However, even after careful systematic 
histological sampling we cannot rule out single remaining tumor cells in the surviving 
animals that might give rise to secondary disease at a later timepoint. Instead we 
observed the formation of scar tissue at the site of glioma implantation. Microglial 
activation and accumulation around the scar was still considerable 6 weeks after 
cessation of IL-12Fc infusion. Despite evidence for a strong immune reaction that 
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must have taken place, we did not detect any symptoms of autoimmunity during the 
course of the experiments.  
3.3.2	  A	  reversal	  of	  the	  GBM	  induced	  immunosuppression?	  
Our preliminary observations in treated animals imply that IL-12 administration i.t. 
allows lymphocytes to access the bulk tumor more readily. The appearance of focal 
tissue destruction in IL-12Fc treated animals - which is more prevalent in 
combination treatment - is in line with decreased BLI readings. Moreover, we see a 
strong increase in CD8+ CTL infiltration, even compared to IL-12 single treated 
animals. These histological findings are in line with the analysis of TILs by flow 
cytometry, which shows an impressive shift towards CTLs at the expense of TH cells. 
Reflecting the clinical outcome, IL-12Fc leads to a clear reversal of Tregs into TH1 
cells, while αCTLA-4 monotherapy has a weaker effect. It seems that local IL-12Fc, 
especially in combination with αCTLA-4 treatment indeed overcomes the suppressive 
microenvironment and leads to an immune-attack against the tumor. However, to 
corroborate this statement, a more detailed analysis of a larger group of samples is 
needed. We will thus assess the number, polarization and activation states of 
macrophages/microglia, NK-cells, CTLs and CD4+ T-cells. In particular, we want to 
determine the number of CD4+ T-cells that express high levels of inducible 
costimulator (ICOS). Numbers of TH cells expressing this costimulatory molecule 
were found to be increased upon CTLA-4 blockade in bladder cancer patients and 
these cells seemed to exhibit elevated effector functions279,280. Also the associated 
vasculature plays an important role in restricting infiltration of effector cells into the 
tumor due to a relative paucity of adhesion molecules281. Even though IL-12 inhibits 
angiogenesis it has been reported to increase the expression of vascular cell adhesion 
molecule-1 (VCAM) and intercellular adhesion molecule (ICAM) on melanoma 
vasculature (1.3.1.1,148). Up regulation of VCAM and ICAM could therefore be 
another reason for an increased influx of effector cells into the tumor. A recent 
publication describes increased levels of soluble CTLA-4 (sCTLA-4) in breast cancer 
patients282. Blockade of sCTLA-4, which is suspected to bind to B7 and thus interfere 
with T-cell activation, could also add to the activation of effector T-cells283,284. 
Whether the effects of CTLA-4 blockade in our model are also attributable to a 
neutralization of circulating sCTLA-4 or CTLA-4 derived from glioma cells remains 
to be investigated.  
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3.3.3	   Translational	   potential	   of	   combination	   therapy	   with	   local	   IL-­‐12Fc	   and	  
systemic	  CTLA-­‐4	  blockade	  
Our findings have the potential for clinical translation. In addition to standard 
treatment, especially surgical debulking, IL-12 could be infused into the resection 
cave via CED285, while CTLA-4 blockade would be applied systemically. Moreover, 
variations of the here reported treatment scheme could also potentially boost adoptive 
immunotherapy or DC-vaccination approaches. The combination of radiation therapy, 
adoptive cell therapy and CTLA-4 blockade has already resulted in superior antitumor 
immunity in the B16 melanoma model70. It remains to be determined which additional 
effects local IL-12 application would unleash. Cellular vaccination and DC 
vaccination approaches have far progressed towards becoming a clinical treatment 
modality, but many are critically dependent on culturing patient derived leukocytes 
and/or tumor cells. Apart from being costly and not always successful, sometimes 
GBMs might simply progress before cells are reasonably expanded in numbers247. 
Local cytokine therapy circumvents these problems entirely. Moreover, application of 
a protein drug has significant advantages over using other delivery systems such as 
viral particles. Not only the large-scale production, but also the local concentration 
and handling of a protein based drug is more easily controllable. In addition, safety 
and efficacy concerns, especially in regards to insertional mutagenesis of lentiviral 
transduction systems or neutralizing immune reactions observed with adenoviral 
vectors remain, despite tremendous progress in these fields286,287. Systemic anti 
CTLA-4 treatment is FDA approved for metastatic melanoma, demonstrates clinical 
benefit116,288 and is further tested for various other solid cancers289. In light of data 
presented here, a combination therapy not only for GBM consisting of CTLA-4 
blockade with local administration of IL-12 is a highly promising candidate for 
immediate clinical translation. 
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3.4	  Concluding	  remarks	  and	  future	  directions	  
Using a syngeneic model and various immune-deficient mice, our data show that IL-
12 induced glioma rejection is critically dependent on both CD4+ and CD8+ T-cells, 
leads to immunological memory, and can be boosted by blockade of the co-inhibitory 
molecule CTLA-4. Combination treatment consisting of local IL-12 and systemic 
CTLA-4 blockade in mice bearing advanced stage gliomas leads to a high proportion 
of survivors. Efforts in the future will aim at a more in depth-analysis of the 
mechanisms of rejection in combination treatment and at validating our results in the 
SMA560 mouse glioma model. Moreover, we are in the process of producing and 
characterizing a human version of the above described IL-12Fc single chain fusion 
protein which should ultimately become a part of combination treatment in humans. 
So far we have focused on the effector mechanisms of IL-12 induced glioma 
rejection. How local IL-12 application influences the priming of this T-cell response 
remains entirely elusive. Therefore we plan to unravel the events leading to the 
successful priming of an adaptive anti-glioma response and the contribution of IL-12 
to this process. 
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4 Methods 
4.1	  In	  vivo	  Manipulations	  
4.1.1	  Animals	  
C57BL/6 mice were obtained from Janvier; b2m-/-, Ia(b)-/-, Il12rb2-/-, Rag1-/-, Rag2-/-
Il2rg-/-, Prf1-/- and  Ifng-/- mice were obtained from Jackson Laboratories. Il15ra-/- mice 
were provided by S. Bulfone-Paus. All animals were kept in house under specific 
pathogen–free conditions at a 12hour light/dark cycle with food and water provided 
ad libitum. All animal experiments were approved by the swiss cantonary veterinary 
office (16/2009). 
4.1.2	  Orthotopic	  glioma	  inoculation	  
Briefly, 6-10 week old mice were i.p. injected with Fluniximin (Biokema, 5mg/kg 
body weight) before being anaesthesized with 3-5% isoflurane (Minrad) in an 
induction chamber. Their heads were shaved with an electric hair-trimmer (Wella). 
After being mounted onto a stereotactic frame (David Kopf Instruments), the animals´ 
scalp was disinfected with 10% iodine solution (Betadine, Mundipharma) and a skin 
incision was made along the midline. Anaesthesia on the stereotactic frame was 
maintained at 3% isoflurane delivered through a nose adaptor (David Kopf 
Instruments). Subsequently, a blunt ended syringe (Hamilton, 75N, 26s/2”/2, 5µl) was 
mounted on a microinjection pump on the manipulator arm and placed 1.5mm lateral 
and 1mm frontal of bregma. The needle was lowered into the manually drilled burr 
hole at a depth of 4mm below the dura surface and retracted 1mm to form a small 
reservoir. Using the microinjection pump (UMP-3, World precision Instruments Inc.) 
2x104 cells were injected in a volume of 2µl at 1µl/min. After leaving the needle in 
place for 2min, it was retracted at 1mm/min. The burr hole was closed with bone wax 
(Aesculap, Braun) and the scalp wound was sealed with tissue glue (Indermil, 
Henkel). 
4.1.3	  In	  vivo	  bioluminescent	  imaging	  
Tumor bearing mice were carefully weighed, anaesthesized with isoflurane (2-3%) 
and injected with D-Luciferin (150mg/kg body weight, Caliper Lifesciences). 
Animals were transferred to the dark chamber of a Xenogen IVIS 100 (Caliper 
Lifesciences) imaging system, anaesthesia was maintained at 2% isoflurane via 
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nosecones. 10min after injection luminescence was recorded. Data was subsequently 
analyzed using Living Image 2.5 software (Caliper Lifesciences). A circular region of 
interest (ROI; 1.46cm ⦰) was defined around the animals´ head and photon flux of 
this region was read out and plotted. 
4.1.4	  Treatment	  of	  established	  gliomas	  
At d21 after implantation of the glioma cells, the tumor bearing animals were evenly 
distributed among experimental groups based on their ROI-photon flux. Animals with 
an ROI flux of less than 1x105 p/s were considered as non-takers and excluded. 40-
48h prior to implantation (2 days before beginning of treatment), osmotic pumps 
(Model 2004, 0.25µl/h; Alzet) were filled with murine IL-12Fc (8.33 ng/µl in PBS) or 
PBS alone and primed at 37°C in PBS. Immediately prior to surgery, mice were 
injected with Fluniximin i.p. (Biokema, 5mg/kg body weight). Mice were 
anaesthesized with 3-5% isoflurane, the scalp was disinfected and a midline incision 
was made. The previous burr hole of the glioma injection was located, the bone wax 
and periost removed and the pump placed into a skin pouch formed at the animal´s 
back. The infusion cannula was lowered through the burr hole 3mm into the putative 
center of the tumor. The cannula was connected to the pump (brain infusion kit III 1-
3mm, Alzet) via a silicon tube and held in place with cyanoacrylate adhesive. The 
skin was sutured with a 4-0 nylon thread. Following surgery, mice were treated for 3 
days with 0.1% (v/v) Borgal (Intervet) in the drinking water. Pumps were explanted at 
day 49. Five doses of anti mouse-CTLA-4 mouse-IgG2b antibodies (clone 9D9, bio-
X-cell)264 or an equivalent volume of PBS were i.p. injected at days 22 (200µg), 26 
(100µg), 29 (100µg), 35 (100µg) and 42 (100µg). For systemic treatment, animals 
received 200µg anti mouse-CTLA-4 and/or 200ng rIL-12 (Peprotech) in PBS starting 
at day 21 via i.p. injection. Treatment was sustained with 100µg anti mouse-CTLA-4 
and/or 100ng rIL-12 three times per week until the end of the experiment. 
4.1.5	  Survival	  analysis	  of	  tumor	  bearing	  animals	  
Tumor bearing animals were monitored by BLI, checked for neurological symptoms 
and weighed weekly until day 21 post glioma inoculation. Gl261 Fc animals 
exhibiting an ROI flux of less than 1x105 p/s at day 21 were considered as non or 
slow-tumor takers and excluded from the survival analysis (5-10%). From day 21 
onwards animals were checked daily. Animals that showed symptoms as apathy, 
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severe hunchback posture and/or weight loss of over 20% of peak weight were 
euthanized. 
 
4.2	  Cell	  culture	  
4.2.1	  Mouse	  glioma	  cell	  lines	  
C57/Bl6 murine glioma (Gl261) cells (kindly provided by A. Fontana, Experimental 
Immunology, University of Zürich) were transfected with pGl3-ctrl (Promega) and 
pGK-Puro (kindly provided by T. Buch, Technical University Munich). Linearized 
constructs were electroporated in a 10:1 ratio using an eppendorf multiporator, then 
selected with 0.8µg/ml puromycin (Sigma-Aldrich) to generate luciferase-stable 
Gl261 cells. A single clone was isolated by limiting dilution and passaged in vivo by 
intracranial tumor inoculation, followed by tumor dissociation after 4 weeks and re-
selection in 0.8µg/ml puromycin. Subsequently, cells were electroporated with 
pCEP4-mIgG3, pCEP4-mIl-12mIgG3 and pCEP4-mIl-23mIgG3 (Eisenring et al, 
2010) and bulk-selected with 0.8µg/ml puromycin and 0.23mg/ml hygromycin 
(Sigma-Aldrich). Cytokine production was detetected by ELISA (OptEIA Il-
12/23p40, BD Pharmingen) and rt-PCR (IgG3fw: ACACACAGCCTGGACGC 
IgG3rev: CATTTGAACTCCTTGCCCCT). Gl261 cells and derived cell lines were 
maintained in Dulbecco’s modified Eagle’s medium (Gibco, Invitrogen) 
supplemented with 10% fetal calf serum (FCS) in presence of selection antibiotics as 
indicated above at 37°C and 10% CO2.  
 
4.2.2	  Proliferation	  assay	  
Gl261, Gl261 Fc, Gl261 IL-12 or Gl261 IL-23 cells (5000 cells/well) were plated into 
a 96-well plate in triplicates. Medium containing 0.5 mCi/ml of [3H]thymidine was 
added and 4 days later we assessed the incorporation with a Filtermate Collector 
(Applied Biosystems) and a scintillation counter (MicroBeta Trilux 1450, Wallac). 
 
4.2.3	  Expression	  and	  purification	  of	  IL-­‐12Fc	  
IL-12Fc was expressed in 293T cells after calcium phosphate-mediated transfection 
according to standard protocols with 45µg of vector DNA (pCEP4-mIL-
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12IgG3)/15cm tissue culture plate. Supernatant was harvested 3 days and 6 days after 
transfection, sterile filtered and diluted 1:1 in PBS. The protein was purified using a 
purifier (ÄktaPrime) over a protein G column (1ml, HiTrap, GE Healthcare) eluted 
with 0.1 M glycine pH 2 and dialyzed over night in PBS pH 7.4. Concentration and 
purity of IL-12Fc was measured by ELISA (OptEIA Il-12/23p40, BD Pharmingen) 
and SDS-PAGE followed by silverstaining and immunoblotting. IL-12Fc was 
detected with a rat anti mouse IL-12p40 antibody (C17.8, BioExpress) and a goat 
anti-rat HRP coupled antibody (Jackson). 
 
4.3	  Analysis	  of	  Tumor	  infiltrating	  lymphocytes	  
4.3.1	  Histology	  
For histology, animals were euthanized with CO2, transcardially perfused with ice-
cold PBS and decapitated. The brain was carefully isolated and the frontal part of the 
cerebrum (for analysis of treated animals only one half of the tumor was used) was 
embedded in optimal cutting temperature compound (O.C.T., Sakura) and snap-frozen 
in liquid nitrogen. Cryosections 5µm in thickness were air-dried for 90min at 25°C 
and fixed for 10min at 25°C with acetone and were then incubated with the following 
primary antibodies: rat anti-CD4 (YTS191) and rat anti-CD8 (YTS169; both provided 
by R. Zinkernagel), rat anti-CD11b (5C6; BMA biomedicals), rat anti–asialo GM1 
(NK cell; 986-10001; Wako Chemicals) or F4/80 (BM8; BMA biomedicals). For 
conventional immunohistochemistry, antibodies were coupled to alkaline phosphatase 
(or Horse Radish Peroxidase, HRP) or were detected with alkaline phosphatase- or 
HRP- coupled secondary antibodies. Staining was visualized with Fast Red as the 
alkaline phosphatase substrate (Refine Detection kit; Leica) or with 3,3'-
Diaminobenzidin (DAB) as the HRP substrate. Alternatively, whole brains were fixed 
in 4% Formalin, embedded in Paraffin and 3µm sections were processed for HE 
staining or immunohistochemistry. Pictures were generated using an Olympus BX41 
light microscope equipped with an Olympus ColorView IIIu camera and Olympus 
cell^B image acquisition software. Low magnification overview pictures of whole 
brain sections were cropped using Adobe Photoshop PS3. 
4.3.2	  Stereometric	  assessment	  of	  tumor	  volume 
Paraffin embedded brains were cut in consecutive coronal sections through the tumor 
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area. Single sections were 5µm thick and cut every 200µm. Overview pictures of the 
single sections were generated using 4x objective of an Olympus BX41 light 
microscope equipped with an Olympus ColorView IIIu camera and Olympus cell^B 
image acquisition software. Single images were merged where necessary. Tumor area 
of single sections was determined using ImageJ (1.43u, NIH) and calculated using the 
analysis tool. Tumor volume was subsequently determined by multiplying the sum of 
the profile areas on all sections with the distance between the sections as described 
in290. Volume/luminescence correlation was subsequently analyzed using Prism 5.0a. 
4.3.3	  Flow	  cytometry	  
The following antibodies were used for flow cytometric analyses: anti-CD45 (30-F11, 
Biolegend), anti-CD11b (M1/70, BD), anti-CD4 (Gk1.5, BioLegend or BD), anti-
CD8 (53-6.7, BioLegend or BD), anti-NK1.1 (PK136, BD), anti-FoxP3 (FJK-16s, 
eBioscience), anti-IFN-γ (XMG1.2, BD), anti-IL-17 (17B7, eBioscience), anti-TNF 
(MP6-XT22, BD). FACS analysis of CNS-invading lymphocytes has been described 
previously. Briefly, mice were euthanized with CO2 and transcardially perfused with 
ice-cold PBS. Subsequently brains were isolated, only the frontal part of the tumor 
bearing cerebral hemisphere (for analysis of treated animals only one half of the 
tumor was used) was cut into small pieces and incubated with DNAseI (0.5mg/ml, 
Sigma) and Collagenase D (0.2mg/ml, Roche) for 30min at 37°C, followed by the 
addition of EDTA (final concentration 5mM) to stop the reaction. Afterwards, the 
tissue was homogenized, filtered through a 70µm nylon filter (BD) and washed with 
PBS. Cells were collected by centrifugation at 450g for 5 min at 4°C, the pellet was 
resuspended in 30% Percoll (GE Healthcare) and centrifuged at 15000g for 30 min at 
4°C. The interphase cells were collected, washed and restimulated for 4 hours at 37°C 
and 5% CO2 in Roswell Park Memorial Institute (RPMI) 1640 medium. RPMI 1640 
was supplemented with 10% FCS and Phorbol 12-myristate 13-acetate (50ng/ml), 
Ionomycin (500ng/µl) and Breveldin A (1µl/ml medium, GolgiPlug™, BD) for 
restimulation and to block intracellular transport. Intracellular cytokine and 
transcription factor staining was performed using the eBioscience FoxP3 buffer set 
following the manufacturer´s instructions. Aquisition was performed on a LSRII 
Fortessa flow cytometer (BD). Data analysis was performed using FloJo Version 9.2 
(TreeStar). Statistical analysis was performed using Prism 5.0a. 
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4.4	  Statistical	  analysis	  	  
For all non-survival analyses of three or more experimental groups a one-way 
ANOVA with Tuckey´s or Bonferroni post-test was performed using GraphPad Prism 
version 5.0a for Mac OSX (GraphPad Software Inc). For statistical analysis of 
Kaplan-Meier survival curves, a Log-rank (Mantel-Cox) Test was used to calculate 
the p-values indicated in respective figures. P values of less than 0.05 were 
considered statistically significant. Analysis was performed with GraphPad Prism 
version 5.0a for Mac OSX (GraphPad Software Inc). 
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Alzheimer’s disease (AD) pathology displays an inflammatory component 
characterized by the presence of pro-inflammatory cytokines particularly in response 
to β-amyloid. Using transgenic APPPS1 mice serving as a model of AD, we observed 
the production of the common interleukin (IL)-12 and IL-23 subunit p40 by 
microglia. Genetic ablation of p40 and two other IL-12/IL-23 subunits, namely p35 
and p19, resulted in a drastic decrease in cerebral amyloid plaque load. Although 
deletion of IL-12/IL-23 signaling from the radiation-resistant glial compartment of the 
brain either by removing p40 or its respective receptors was most efficient in 
mitigating cerebral amyloidosis, peripheral administration of a neutralizing anti-p40 
antibody likewise resulted in a significant reduction of cerebral β-amyloid in APPPS1 
mice. Our results suggest that IL-12/IL-23 signaling exacerbates cereberal 
amyloidosis and poses a novel potential pharmacological target to combat AD. 
 
With more than 35 million affected people worldwide, Alzheimer’s disease (AD) is 
the most common form of dementia and a rising threat for public health (1). AD is a 
primary neurodegenerative disorder characterized by three major pathological 
hallmarks: neuronal loss, neurofibrillary tangles and β-amyloid (Aβ) plaques (1). Aβ 
peptides, the main component of extracellular Aβ plaques, are derived from a 
membrane bound precursor molecule by subsequent cleavage events (2). Disease 
causing mutations in familial early-onset AD (FAD) were found to affect generation 
of Aβ peptides. Based on the identification of such FAD mutations, the amyloid 
cascade hypothesis was proposed, which puts Aβ accumulation at the core of AD 
pathogenesis (3). Insights from the analysis of FAD-causing mutations guided the 
development of transgenic mouse models that closely recapitulate Aβ plaque 
pathology (4). As observed in human AD, Aβ plaques in transgenic animals are 
surrounded by reactive astroglia and microglia (5). Especially the role of microglia 
and blood-derived myeloid cells in disease initiation and propagation is a matter of 
intense debate (6). Besides reports on the impact of blood-derived macrophages on 
Aβ plaques, we recently demonstrated that the ablation of CNS-resident microglia in 
AD mouse models did not influence Aβ plaque load, at least when lacking for a 
limited time of up to 30 days in two mouse models of cerebral amyloidosis (7). 
However, increased expression of pro-inflammatory cytokines such as IL-1β and 
TNFα has been described as the cellular local response to Aβ plaques (8) While 
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ablation of IL-1β or IL-6 signaling in AD mice did not change plaque pathology, 
neutralization of Prostaglandin E2 or deletion of CD40L resulted in a moderate 
reduction of the Aβ plaque load (9). Despite descriptive evidence for differential 
expression of inflammatory mediators in AD (5), studies on expression patterns of 
proinflammatory cytokines are rather limited. This may explain why a potential 
pathogenetic or exacerbating role of the immune system in the pathogenesis of AD 
remains largely unknown. 
  Glial cells, and in particular microglia, which typically closely associate with 
Aβ plaques, are reported to be a major source of proinflammatory cytokines in many 
CNS diseases including AD (5) and murine models thereof (8). In particular, TNFα 
has been described to have a major impact on neurodegeneration in mice (10, 11). 
Also IL-12 and its close relative IL-23 have recently been reported to not exclusively 
modulate adaptive immune responses, but were also observed to orchestrate the 
activity of innate immune cells (12, 13), which have been shown to play a role in AD 
pathology (6, 9). IL-12 and IL-23 share a common subunit (IL-12/23p40; termed p40 
throughout the manuscript) as well as the signaling chain of their respective receptors 
(IL-12Rβ1). We assessed the expression of IL-12, IL-23 and TNFα in amyloidosis-
prone APPPS1 (14) mice. Flow cytometric analyses of APPPS1 mouse brains 
revealed a significant increase in the mean fluorescent CD45 intensity of CD45int 
CD11b+ microglia when compared to wild-type littermates (Fig. 1A). Moreover, we 
found a weak increase in TNFα in CNS-resident microglia (CD45int CD11b+) of 
APPPS1 mice (data not shown). However, levels of p40 were specifically and 
significantly increased in the FACS-sorted fraction of APPPS1-derived microglia, but 
not by invading myeloid cells (CD45high CD11b+) or lymphocytes (CD45high 
CD11b-) (Fig. 1B).  Quantitative PCR analysis of FACS-sorted microglia (CD45int 
CD11b+) vs other brain cells (CD45- CD11b-) confirmed our findings: IL-23p19, p40 
and TNFα mRNA was robustly up-regulated by microglia derived from the brains of 
APPPS1 mice, while we observed only a slight increase in IL-12p35 expression by 
the CD45- CD11b- fraction (Fig. 1C).  
 To directly study the potential impact of this increase in IL-12 and IL-23 
expression on Aβ pathology we crossed APPPS1 mice - a reliable,  aggressive and 
early-onset model of cerebral amyloidosis without significant inter- or intraindividual 
variability (14) - to mice deficient in (i) p40 (Il12b-/-) (15), i.e. lacking the common 
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component of IL-12 and IL-23, (ii) p35 (Il12a-/-) (16) lacking IL-12 and (iii) p19 
(Il23a-/-) (17) devoid of IL-23. At 120d of age, when cerebral amyloidosis is very 
robust, APPPS1 mice deficient for p40, p35 as well as for p19 showed a drastic 
reduction in cortical Aβ plaque load when compared to APPPS1 mice. This effect was 
most pronounced in APPPS1 mice lacking p40, as assessed by morphometric analyses 
(Fig. 2 A and B). To determine whether Aβ-reduction in cytokine-deficient mice was 
merely due to a delay in amyloid plaque formation, we also analyzed Aβ-plaque load 
at 250d. Again, APPPS1xIl12b-/- mice exhibited a significant reduction in Aβ plaque 
burden compared to age and sex-matched controls (Fig. 2C). The reduction in plaque 
burden was accompanied by a reduced activation of astrocytes and microglia (Fig. 
2D; fig. S1).  
 Biochemical analyses corroborated the finding of a reduced Aβ burden due to 
the lack of p40 in APPPS1 mice: at 250d Aβ40 and Aβ42 in the soluble (SDS) as well 
as in the insoluble (FA) fraction were reduced by approximately 50% in 
APPPS1xIl12b-/- mice when compared to APPPS1 control mice (Fig. 3, A and B). 
p40 does not impact the cleavage pattern of the γ-secretase, as the decrease in Aβ was 
not accompanied by a shift in the ratio of Aβ40 and Aβ42 (Fig. 3C). Expression of 
APP and the ratio of α - and β -CTF, which are direct substrates of the γ -secretase, 
were also unchanged in APPPS1xIl12b-/- mice (Fig. 3D). In addition, levels of 
insulin-degrading enzyme (IDE) and neprilysin, the two major Aβ degrading enzymes 
in the brain (18), were unchanged in APPPS1xIl12b-/- mice (Fig. 3E) indicating that 
the production and processing of APP in the absence of p40 are unaltered. We also 
detected no significant differences in the expression pattern of 84 murine AD-related 
genes including γ -secretase components and major APP processing secretases in 
brains of 250d old APPPS1xIl12b-/- mice when compared to APPPS1 mice (fig. S2). 
Taken together, loss of IL-12/IL-23 genes did not have a measurable impact on the 
biochemical apparatus accountable for amyloid formation nor is there any evidence 
for an alteration of Aβ amyloid due to interference of the targeted alleles with the 
APPPS1 transgene.  
 To dissect the site of p40 action in APPPS1 mice, bone marrow (BM) 
chimeric mice lacking p40 in the radio-resistant (i.e. the CNS) or in the radio-
sensitive, hematopoietic compartment were generated. Flow cytometric analyses of 
blood for congenic donor markers six weeks after adoptive transfer demonstrated 
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successful reconstitution. Microglia, at the time of termination of the experiments, 
were - as expected and previously shown (19) – not replaced by CNS-invading donor 
cells (fig. S3). APPPS1xIl12b-/- recipients receiving Il12b-/- bone marrow (Il12b-/- 
àAPPPS1xIl12b-/-) retained the previously described p40-dependent phenotype 
(Fig. 4A), indicating that irradiation and reconstitution per se did not affect cerebral 
amyloidosis. Il12b+/+ àAPPPS1xIl12b-/-, which leads to the loss of the p40 gene in 
the radio-resistant compartment, displayed a reduction in Aβ plaque load similar to 
unmanipulated APPPS1xIl12b-/- mice (Fig. 4A). Importantly, Il12b-/-
àAPPPS1xIl12b+/+ chimeric mice showed no decrease in Aβ plaque load when 
compared to the baseline control (Fig. 4A). This indicates that p40 expression by 
CNS-resident cells is capable of modulating Aβ plaque load in Alzheimer’s APPPS1 
mice. We created additional BM chimeric mice lacking IL-12β1 receptor (Il12rb1-/-), 
which is a central component of both IL-12 and IL-23 receptors and required for 
conducting p40-mediated signals (20). This approach also allowed determining the 
target of CNS-derived and Aβ-mediated p40 expression. Consistent with a role of IL-
12/IL-23 signaling in exacerbating amyloid formation, the absence of IL-12β1 
receptor in CNS-resident cells resulted in a drastic reduction of Aβ plaque burden 
(Fig. 4B). These results indicate that lack of IL-12/IL-23 signaling in the radio-
resistant compartment of the CNS, i.e. in microglia, suffices to reduce cerebral 
amyloidosis. 
 In order to translate our findings into a more clinically relevant context, we 
blocked p40 signaling in APPPS1 mice by injecting neutralizing anti-p40 antibodies 
(C17.8; rat IgG2a) (21). Notably, morphometric analyses of the Aβ burden of 
APPPS1 mice taken at 120 days revealed an overall profound and statistically 
significant reduction of Aβ burden exclusively in the anti-p40 treatment group (Fig. 
4C). All anti-p40 antibody-treated mice revealed p40 blocking activity in the serum at 
the end of the experiment as assessed by ELISA (data not shown). The fact that there 
was some variation in four out of 8 anti-p40 antibody-treated APPPS1 mice most 
likely is attributable to an inevitable variation in the efficacy of the injected antibody 
to cross the blood brain barrier and to exert its effect in the CNS compartment. 
 
The discovery of reduced pathology in transgenic AD mice upon genetic 
manipulation of IL-12 and / or IL-23 signaling pathways – the strongest effect was 
seen when both IL-12 and IL-23 were lacking - supports recent findings of a 
Appendix                                                         IL-12/IL-23 influence AD Aβ pathology 
 
 114 
pathogenetic contribution of the immune system in AD (9, 22).  While it is not clear 
whether inflammation is causal or an accompanying process of AD pathogenesis, it is 
widely accepted that manipulation of the immune system can be utilized to influence 
disease progression. Epidemiological studies have suggested that nonsteroidal anti-
inflammatory drugs (NSAIDs) reduce the risk to develop AD, but several prospective 
placebo-controlled trials testing the efficacy of NSAIDs in AD failed (23). Either anti-
inflammatory treatment needs to be applied at early disease stages, or other, more 
specific immune actions need to be targeted, which are not affected by NSAIDs.  Our 
results appear to be of substantial relevance for generating novel NSAID-independent 
interventional or prophylactic strategies to manipulate AD pathology, e.g. to utilize 
blocking molecules against the common IL-12/IL-23 subunit p40.  
While IL-12 and IL-23 have been implicated in a variety of diseases including 
bacterial infections (24), multiple sclerosis (MS) (25), and autoimmune disorders such 
as Crohn’s disease (26) and psoriasis (27), the regulation and obvious role of 
proinflammatory cytokines including IL-12 and IL-23 in AD has not been established. 
Only few published biomarker studies describe mutually contradictory IL-12 levels of 
peripheral blood or CSF samples derived from AD patients - IL-12 was reported 
either to be increased, decreased or even unaltered (28-30) -, while data on IL-23 in 
AD has not been reported to date. Indirect clues for a potential implication of IL-12 in 
the regulation of AD pathology may come from Alzheimer’s Aβ vaccination 
approaches in AD mice: such immunization experiments resulting in a robust 
reduction in amyloid burden were described to go along with a decrease in IL-12Rβ1 
receptor (31), which is essential for IL-12/IL-23 signaling. Similarly, treatment of AD 
mice with the angiotensin receptor blocker Losartan decreased amyloid plaque load 
and was accompanied by a reduction of plasma IL-12 levels (32). A major caveat to 
attributing a defined function to cytokines (and their receptors) of the IL-12 
superfamily in health and disease is that they are heterodimers and that genetic 
targeting of the one or the other component inevitably results in the loss of (at least) 
two cytokines.  
Immune factors such as cytokines and chemokines have been reported to mediate 
changes on AD plaque pathology primarily via the activation and recruitment of 
microglia and peripheral myeloid cells (33, 34). Since p40 in AD mouse brains is 
upregulated by microglia, whereas deficiency of p40 in CNS-resident microglia 
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suffices to reduce Aβ burden, microglia appear to be central to mediate p40-related 
effects on Aβ burden. A similar role of microglia has been described in a murine 
model of MS, where p40 expression in the radio-resistant compartment was 
demonstrated to be crucial for the sustenance of neuroinflammation (35). However, 
we assume that p40 (or its cellular source) within the CNS needs to be absent for a 
prolonged period of time in order to confer Aβ-reducing effects, since ablation of 
resident microglia and CNS-invading myeloid cells in AD mice for up to 30 days did 
not result in significant changes in amyloid plaque load – in contrast to bone marrow-
derived myeloid cells entering the brain, which have been described to be capable of 
reducing Aβ burden (6, 33, 34, 36). Taken together, our data provide compelling 
evidence that IL-12/IL-23 signaling is crucially involved in controlling the amount of 
a central component of AD pathology, namely Aβ burden. Manipulation of IL-12 and 
/ or IL-23 signaling pathways in an aggressive, early-onset mouse model of cerebral 
amyloidosis drastically reduces Aβ pathology. IL-12, IL-23 and their signaling 
pathways thus appear to be novel and NSAID-independent druggable targets to fight 
AD.  Even though the precise mechanistic underpinnings for the disease exacerbating 
effects remain under investigation, the fact that clinical trials using IL-12 blocking 
antibodies for the treatment of psoriasis (37), Crohn’s disease (38) and MS (39) 
previously have been executed, i.e. FDA-approval and data on the safety and 
tolerance of IL-12 blocking antibodies in humans exist, a first translational prevention 
and / or treatment trial in mild cognitive impairment (MCI) or (prodromal) AD 
patients could be initiated without delay. 
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Figure Legends 
 
Fig. 1. Upregulation of proinflammatory cytokines in the glial compartment of 
APPPS1 mice  
(A,B) cells isolated from brains of 120 day old female APPPS1 (n = 5) and littermate 
control (n = 3) mice were stained for CD45, CD11b and Il-12/23p40 and analyzed by 
flow cytometry, (A) Dot plots depict CD45hi/CD11bneg (lymphocytes, red), 
CD45hi/CD11bpos (CNS-invading myeloid cells, green), CD45intermediate (int)/CD11bpos 
(microglia, black) and double negative populations (other CNS cells, grey) in wild-
type (wt) littermates and APPPS1 transgenic animals after gating on live singlet 
leukocytes. Scatter plot on the right shows the mean fluorescent intensity (MFI) of the 
CD45 staining for the CD45int/CD11bpos population. (B) Populations in (A) were 
plotted for CD45 and intracellular IL-12/23 p40. Depicted gate illustrates the amount 
cells expressing p40 in the CD45int/CD11bpos population. Similar gates were used for 
all other populations (not shown). Graph (right) displays percentage of p40 positive 
cells in wt and APPPS1 mice. (c) Gene expression of IL-23a, IL-12b, IL-12a and 
TNFα in FACS-sorted CD45int/CD11bpos microglia and a CD45neg/CD11bneg control 
population isolated from 120 day old APPPS1 and control mice (pooled samples, n = 
6 males / group). Depicted is the fold change in expression, normalized to 
Hypoxanthin-Guanin-Phosphoribosyltransferase (HPRT) levels. n.d.: not detectable; 
error bars depict s.e.m. 
 
Fig. 2. Genetic deletion of IL-12 and / or IL-23 subunits reduces Aβ burden in 
APPPS1 mice  
(A) Aβ burden in cytokine-deficient APPPS1 mice was assessed by 
immunohistochemical staining using the β -amyloid reactive antibody 4G8 (upper 
row: low magnification pictures, scalebar 500µm; lower row: higher magnification 
images used for morphometric quantification, scalebar 200µm). (B) Morphometric 
analysis of β-amyloid covered area in APPPS1 mice lacking the IL-12 and / or IL-23 
subunits p40 (Il12b-/-, n = 9), p19 (Il23a-/-, n = 8) or p35 (Il12a-/-, n = 11) at 120d of 
age, compared to control Alzheimer’s APPPS1 mice with functional IL-12 and / or 
IL-23 signaling (n = 16). (C) Aβ burden at 250d of age in APPPS1 mice compared to 
APPPS1xIl12b -/- mice (low magnification picture, scalebar 500µm; insert:  scalebar 
200µm; right: morphometric quantification of APPPS1 (n = 9) and APPPS1xIl12b -/- 
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(n = 6) mice). (D) Immunohistochemical analysis of microglia/macrophages (left: 
histological panel and morphometric quantification for Iba1) and astroglia (right: 
histological panel and morphometric quantification for GFAP) at 250d of age in 
APPPS1 (n = 9) and APPPPS1xIl12b-/- (n = 6) animals, scalebars 100µm. Each dot 
represents the mean of Aβ plaque load, Iba1- or GFAP-covered area of one mouse.  
 
Fig. 3. Genetic deletion of IL-12/IL-23 p40 reduces Aβ plaque burden in APPPS1 
mice without altering amyloid precursor protein (APP) processing  
(A-E) Biochemical analysis was performed on brain homogenates of APPPS1 and 
APPPS1xIl12b -/- mice at 250d of age. (A) Quantification of Aβ40 and Aβ42 levels 
using the MesoScale ELISA system in the soluble (SDS, left panel) and insoluble 
(FA, right panel) fraction.  (B) Levels of Aβ total and human (transgenic) APP in the 
soluble (SDS) fraction (left panels) were assessed by Western blot analysis using the 
6E10 antibody for detection and densitometric analysis thereof. Aβ total levels were 
analysed in a similar fashion in the insoluble (FA) fraction (right panel). (C) Aβ40 
and Aβ42 species in the soluble (left panel) and insoluble (right panel) fraction were 
separated using a specialized SDS-Urea gel system (7), detected with the 6E10 
antibody and quantified by densitometry. (D) Expression levels of endogenous murine 
and transgenic human APP and major C-terminal cleavage products of APP (CTFα 
and CTF) were assessed (left panel) using the APPct antibody and quantified as above 
(right panel, which also includes quantification of the Western blot shown in (B)). (E) 
Expression levels of the major Aβ degrading enzymes insulin degrading enzyme 
(IDE; left panel) and neprilysin (right panel). Representative Mesoscale results, 
Western blot images and results of densitometric quantification of at least 3 
independent experiments are shown (n = 3-7 mice per group). GAPDH or β -Actin 
were used as control for quantification. Error bars depict s.e.m.  
 
Fig. 4. Deficiency of IL-12/IL-23 signaling in the radioresistant compartment or 
peripheral administration of anti-p40 antibodies to Alzheimer’s APPPS1 mice is 
sufficient to reduce Aβ plaque load in APPPS1 mice  
Aβ plaque load assessed as in figure 2 at 120d of age, either 11 weeks after 
reconstitution (A and B); or 13 weeks after beginning of antibody treatment (C and 
D). (A) APPPS1 or APPPS1xIl12b -/- mice were lethally irradiated at 6 weeks of age 
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and reconstituted with bone marrow isolated from C57BL/6 mice (wt) or Il12b-/- mice 
of the same age (n = 3-7 animals per experimental group). Shown is one of two 
representative experiments. (B) Il12rb1-/- chimeric APPPS1 mice were generated as 
above (n = 4-8 animals per experimental group). (C and D) APPPS1 mice were 
treated with anti-p40 antibodies (C17.8; n=8) or isotype control antibodies (2A3; 
n=4), twice a week starting at 4 weeks of age until 120d of age. (C) Representative 
overview and high magnification images of plaque burden in treated animals 
(scalebars as in Fig. 2). (D) Morphometric analysis of Aβ covered area in antibody 
treated mice. Each dot represents the mean of the morphometrically assessed Aβ 
plaque load of one mouse. 
  
Appendix                                                         IL-12/IL-23 influence AD Aβ pathology 
 121 
Figures: 
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Materials and Methods 
Animals  
Transgenic APPPS1 mice harboring the Swedish amyloid precursor protein 
(APP) mutation KM670/671NL in conjunction with the presenilin 1 mutation L166P 
(14) were generously provided by Mathias Jucker. Heterozygous APPPS1+/- mice 
(termed APPPS1 mice throughout this manuscript) were crossed either to Il12b-/- (15), 
to Il12a-/- (16) or to  Il23a-/- (17) mice. Negative littermate controls (i.e. APPPS1+/- 
mice exhibiting functional Il23a, Il12a and Il12b cytokine genes) were obtained by 
crossing APPPS1+/-xIl23a+/- mice to APPPS1-/-xIl23a+/- mice, APPPS1+/-xIl12a+/- 
mice to APPPS1-/-xIl12a+/- mice and APPPS1+/-xIl12b+/- mice to APPPS1-/-xIl12b+/- 
mice. For obtaining donors for adoptive transfer experiments, Il12b-/- and Il12rb1-/- 
animals were bred onto a CD45.1-C57BL/6 background. Il12a-/-, Il12rb1-/-, Il12b-/- 
and CD45.1-C57BL/6 animals were purchased from Jackson Laboratory, Il23a-/- mice 
were obtained from Genetec, CD45.1-C57BL/6 mice were obtained from Janvier. All 
animals were kept under specific pathogen free conditions on a 12 hour light/dark 
cycle, food and water was provided ad libitum. All animal experiments were 
approved by the swiss cantonary veterinary office (107/2008) or by the regional 
offices for health and social services in Berlin (O 0132/09). 
 
Generation of bone marrow chimeric mice  
Bone marrow (BM) chimeras were generated as described previously (19, 40). 
Briefly, donor mice (CD45.1) were euthanized with CO2, BM cells were isolated by 
flushing femur and tibia with ice cold phosphate buffered saline (PBS), mashed 
through a 70µm cell strainer followed by a washing step with PBS. CD45.2 congenic 
recipient mice (6 weeks old) were lethally irradiated with 1100 rads (split dose) and 
intravenously injected with an equal number of donor bone marrow cells (6-12x106 / 
recipient). Engraftment took place over 4-6 weeks of recovery. Blood chimerism was 
assessed via flow cytometry 6 weeks after reconstitution and at the end of the 
experiment (120d of age) using antibodies against CD45.1, CD45.2 and PanCD45 
(BD).  
 
Antibody treatment 
A single intraperitoneal (i.p.) injection of 0.5 mg of anti-mouse p40 antibody 
(clone C17.8, rat IgG2a) or of the respective rat isotype control (clone 2A3, rat 
IgG2a) at 4 weeks of age was followed by biweekly i.p. injections of 0.25 mg of the 
respective antibodies until the end of the experiment (120 days of age). Antibodies 
were diluted in phosphate buffered saline (PBS). 
 
Flow cytometry  
The following antibodies were used for flow cytometric analyses: PacificBlue-
conjugated anti-CD45 (Biolegend), APC-anti-CD11b (BD), FITC-anti-TNF (BD) and 
PE-anti-IL12/23-p40 (BD). FACS analysis of CNS-invading lymphocytes has been 
described previously(19). Briefly, mice were euthanized with CO2 and transcardially 
perfused with ice-cold PBS. Subsequently brains were isolated and olfactory bulbs 
and cerebella removed. All manipulations were performed on ice. Brain samples were 
pooled according to genotype (where indicated in figure legends), cut into small 
pieces and incubated with DNAseI (0.5 mg/ml, Sigma) and Collagenase D 
(0.2 mg/ml, Roche) for 30 min at 37°C, followed by the addition of EDTA (final 
concentration 0.005 M) to stop the reaction. Afterwards, the tissue was homogenized, 
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filtered through a 70µm nylon filter (BD) and washed with PBS. Cells were collected 
by centrifugation at 450g for 5 min at 4°C, the pellet was resuspended in 30% Percoll 
(GE Healthcare) and centrifuged at 15000g for 30 min at 4°C. The interphase cells 
were collected, washed and subjected to flow cytometric staining according to 
standard protocols. Where necessary, cells from individual animals were split in two 
fractions for surface and intracellular stainings. For intracellular cytokine staining 
(ICS), cells were cultured in RPMI containing 10% fetal calf serum for 4 h in the 
presence of Brefeldin A (1µl/1ml medium, GolgiPlug™, BD) and subsequently 
washed, fixed and permeabilized according to standard protocols. Analysis was 
performed either on a FACSCanto II (BD) or on a LSR II Fortessa (BD). For cell 
sorting a FACSAria (BD) was used, whereby the purity of sorted populations was 
routinely above 95%. After sorting, cells were immediately lysed and RNA was 
isolated. 
 
cDNA synthesis and quantitative real-time PCR  
RNA was isolated from cells using an RNeasy Plus Kit (Qiagen) according to 
the manufacturers instructions. SuperScriptIII (Invitrogen) was used for reverse 
transcription using poly-d(T) Primers. Quantitative PCR was performed on a BioRad 
iCycler instrument using Platinum SYBR Mix (Invitrogen) and the primer (5´ - 3´) 
combinations below:  
IL-12/IL-23p40: GACCATCACTGTCAAAGAGTTTCTAGAT,  
AGGAAAGTCTTGTTTTTGAAATTTTTTAA 
Il-23p19: AGCGGGACATATGAATCTACTAAGAGA, 
GTCCTAGTAGGGAGGTGTGAAGTTG 
Il-12p35: TACTAGAGAGACTTCTTCCACAACAAGAG, 
TCTGGTACATCTTCAAGTCCTCATAGA,  
TNFα: CATCTTCTCAAAATTCGAGTGACAA, 
TGGGAGTAGACAAGGTACAACCC 
HPRT: GACCGGTCCCGTCATGC, TCATAACCTGGTTCATCATCGC.   
Subsequent analysis was performed with BioRad iQ5 Software using the ΔCt or 
Δ/ΔCt method. Specificity of amplification was assessed by melting curve analysis 
and gel electrophoresis of amplicons. 
  
Histology 
Formalin fixed and paraffin-embedded brains were processed for 
immunohistochemical analysis and subsequent morphometric analysis as described 
previously(7). Aß deposition, congophilic amyloid, and the number of micro- and 
astroglia was assessed by measuring the immunostained area of 3 cortical regions 
representing the frontal, parietal and occipital cortex (each 1,4 mm2) on every 50th 
systematically sampled 6µm thick Aß-immunostained, Congo red-stained, or Iba1-
immunostained section. The stereomorphologic analysis of 27 defined regions per 
mouse brain was performed with the aid of the Cell D software (Olympus, Tokyo, 
Japan) using the color filter and phase analysis tool. For low magnification pictures 
histological slides were scanned and processed using VMscope software. 
Immunohistochemical stainings were performed using the Vectostain Elite ABC Kits 
(Vector Laboratories; Burlingame, CA). The following primary antibodies were used: 
mouse anti-human Aß antibody 4G8 (Covance, Princeton, NJ); polyclonal antibody to 
ionized calcium binding adapter molecule 1 (Iba1; Wako, Richmond, USA); 
polyclonal antibody to glial fibrillary acidic protein (GFAP; Dako, Hamburg, 
Germany). All polyclonal antibodies were used at a dilution of 1:2000. All other 
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histological stains (Congo red; H&E) were done according to standard laboratory 
procedures. 
 
Electrochemiluminescence linked immunoassay for human Aβ  
Frozen brain hemispheres were homogenized following published 
protocols(41) with slight modifications. Briefly, frozen cerebral hemispheres were 
homogenated in PBS/1% SDS including protease inhibitors (Roche, Cat. No. 
1836153) and centrifuged at 100.000g for 1 hour. The supernatant was collected as 
SDS-soluble Aβ fraction and the pellet was resuspended in 70% formic acid. After 
incubation on ice and frequent vortexing samples were centrifuged again for 1 hour at 
100.000g. The supernatant was considered the insoluble fraction. Samples were 
diluted to fit the standard samples (Abeta Peptide 3-Plex) and were analysed on a 
MS2400 using MSD 96-well MultiSpot Human 6E10 Abeta Triplex Assay (Meso 
Scale Discovery, Gaithersburg, MD) according to manufacturers instructions. 
  
Western Blot  
Urea-based electrophoresis and SDS-PAGE was performed to assess Aβ and 
APP as well as IDE-1 and neprilysin levels. Electrophoresis was carried out according 
to previously published protocols(42) using anti-Aβ 6E10 (Covance, Princeton, 
USA), anti-APPct (Sigma-Aldrich, Schnelldorf, Germany), anti-Neprilysin sc-46656 
(Santa Cruz Biotechnologies, Santa Cruz, USA) and anti-IDE (Calbiochem, 
Nottingham, UK) antibodies. As internal controls monoclonal anti-GAPDH antibody 
(Biodesign, Saco, USA) or monoclonal anti-β-Actin (Abcam, Cambridge, UK) 
antibodies were used. Anti-mouse and anti-rabbit HRP conjugated secondary 
antibodies were purchased from GE healthcare (Munich, Germany). 
  
Statistical analysis 
Student´s t-test was used for statistical analysis of pairwise comparisons of 
experimental groups. Level of significance was p< 0.05 if not otherwise specified. For 
the antibody treatment groups Abeta covered region was analyzed by means of a 
mixed-effects ANOVA model with fixed effects for mice group, region, step and 
level. A step-by-region interaction was also included in the model. The study design 
feature of having multiple observations per mouse was accounted for by including a 
random effect per mouse. Experimental groups were compared by t-test based 
statistics. 
 
PCR array 
RNA was isolated from frozen hemibrains of 250d old APPPS1 and 
APPPS1xIl-12b-/- mice using the peqGold TriFast/Chloroform method according to 
manufacturer´s instructions (peqlab, Erlangen, Germany). RNA was resuspended in 
100µl DEPC-treated water. Concentration of total RNA was determined using a 
TECAN® fluorescence plate reader (Tecan, Männedorf , Swizerland). In addition, 
RNA quality was controlled using the Agilent Bioanalyzer RNA nano chip. Only 
samples with a RIN >7 were used for subsequent analysis. Synthesis of cDNA using 
the RT2 First Strand kit (SA Biosciences, Frederick, USA) as well as PCR array 
analysis (PAMM-057E, SA Biosciences, Frederick, USA) was performed according 
to manufacturer´s instructions. The ABI 7900HT cycler was used for PCR array 
analysis. Data analysis was performed with the ABI software and the SA Biosciences 
PCR array data analysis software following the manufacturer´s instructions. 
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Figure S1. 
Reduced CD45 expression in microglia of plaque-bearing APPPS1xIl12b-/- mice  
120 day old female APPPS1 (n = 5) and APPPS1xIl12b-/- (n = 4) brain homogenates 
upon density gradient centrifugation were stained for CD45 and CD11b and analyzed 
by flow cytometry, gated on live singlet cells. Dot plots depict CD45hi/CD11bneg 
(lymphocytes, red), CD45hi/CD11bpos (CNS-invading myeloid cells, green), 
CD45intermediate (int)/CD11bpos (microglia, black) and double negative populations (other 
CNS cells, grey) in wt littermates and APPPS1 transgenic animals. Scatter plot on the 
right shows the mean fluorescent intensity (MFI) of the CD45 staining for the 
CD45int/CD11bpos population. No apparent changes were detected for any other 
population (data not shown). 
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Figure S2. 
Mouse Alzheimer’s disease PCR array PCR array analysis using the SA Bioscience 
Mouse Alzheimer’s disease PCR array (PAMM-057E) to study the gene expression 
profiles of 84 murine AD-related genes (including Psen1, Psen2, BACE1, BACE2, 
Adam9, Ide and Apoe; for comprehensive overview see the following link: 
http://www.sabiosciences.com/rt_pcr_product/HTML/PAMM-057A.html) in 250d 
old APPPS1xIl12b -/- mice compared to age- and sex-matched APPPS1 mice (n = 4 
per group). Vertical pink lines indicate the desired 2-fold up- or downregulation, 
while the horizontal blue line indicates the statistical significance at a p-value of 
p=0.05  
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Figure S3. 
Analysis of chimerism in blood and brain 
(A) Bone marrow recipients as depicted in Fig. 4 carry the congenic marker CD45.2, 
whereas bone marrow donors (wt, Il12b-/- or Il12rb1-/-) are CD45.1 positive. (B) 
Blood chimerism: flow cytometric analysis of blood for the congenic markers CD45 
pan (recognizing both CD45.1 and CD45.2), CD45.1 and CD45.2 at 6 weeks after 
adoptive transfer of bone marrow and at the endpoint of the experiment. Timepoint at 
6 weeks depicts the mean percentage and standard deviation of CD45.1 positive blood 
lymphocytes of individual mice, timepoint 11 weeks (120d) displays the mean 
percentage and standard deviaton of pooled blood samples from all experimental 
groups (see Fig. 4). (C) Brain chimerism: representative dot plot of cells isolated from 
pooled cerebral hemispheres of Il12b-/- > APPPS1xIl12b-/-mice (as depicted in Fig. 4). 
Cells were stained for CD45 pan, CD45.1, CD45.2 and CD11b. Dead cells and 
duplets were excluded. Left dot plot shows all CD45 positive cells (CD45 vs CD11b), 
right dot plot shows only the radio-resistant CD45.2 pos recipient-derived cells. Note 
that only lymphocytes (CD45hi/CD11bneg) are being replaced, while microglia 
(CD45int/CD11bpos) is not exchanged by this procedure 
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